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ABSTRACT 
Molecular and Cellular Signaling Mechanisms Elucidating Aldose Reductase Mediated 
Ischemia-Reperfusion Injury in the Myocardium 
Mariane Abdillahi 
This dissertation serves to analyze the molecular and cellular signaling mechanisms by which 
aldose reductase (AR) contributes to ischemia/reperfusion (I/R) injury, specifically in the 
myocardium.  It provides a comprehensive overview of the pathophysiology associated with 
acute coronary syndromes, the mechanisms of normal myocardial substrate metabolism, and how 
metabolism is altered under ischemic conditions.  Specific chapters in this dissertation aim to 
elucidate whether AR pathway mediated I/R injury is linked to changes in glycogen synthase 
kinase 3β (GSK3β) phosphorylation, and whether an increased flux via AR and resultant I/R 
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Acute Coronary Syndromes 
Cardiovascular diseases which are defined as diseases of the heart and vasculature are the 
number one cause of death in men and women in the United States [1].  It has been estimated 
that CVD and stroke related costs for 2010 are approximately $503.2 billion and are expected to 
triple by the year 2030 [1]. Through several studies, it has become increasingly evident that poor 
nutrition as well as lack of physical activity play large roles in cardiovascular disease induction 
and progression [2].  Diabetes is a major risk factor for developing CVD and heart failure; 
however there is an increased prevalence of people who suffer from diabetic cardiomyopathy, 
defined as heart failure independent of coronary artery disease [3].  The increased prevalence of 
diabetes and CVD in the United States can be attributed to the sedentary lifestyle and poor eating 
habits, however other factors can play a role including age, smoking, and a previous family 
history of CVD. 
The most common cause of ischemic disease is atherosclerosis [4-5].  With disease progression, 
atherosclerotic plaque buildup in the vasculature can erode and rupture causing a thrombus to 
develop in arteries which may ultimately reduce or stop blood flow necessary for tissue survival.  
Acute coronary syndromes (ACS) are conditions which abruptly stop blood flow to the heart due 
to development of thrombosis on atherosclerotic plaques.  Plaque disruption and thrombosis 
development are the main cause of ACS, which include unstable angina, acute myocardial 
infarction and sudden ischemic death [4-7].  A reduction in blood flow ultimately leads to 
myocardial infarction and/or tissue death (necrosis).  Patients with acute coronary syndromes are 
at high risk for myocardial infarctions and/or death and the risks are largely associated with the 




Angina describes chest pain, or discomfort associated with myocardial infarction and is a typical 
symptom of patients who present with ACS.  Patients who report short episodes of chest pain as 
a result of activity such as exercise that increases myocardial oxygen demand are described 
clinically as presenting with stable angina.  Unstable angina, on the other hand, is characterized 
as the unpredictable occurrence of chest pain either at rest or during exercise and without 
elevation of ST (period of systolic depolarization) segment on the electrocardiogram (ECG) or 
without detectable biomarkers of necrosis.  If biomarkers of necrosis such as Troponin I or 
Troponin T are detected, patients are described clinically as presenting with non ST elevation 
myocardial infarction (NSTEMI) [8-11].  Those patients categorized with ST segment elevation 
(STEMI) typically also have detectable levels of necrotic biomarkers in their blood.  Use of 
clinical myocardial damage biomarkers are no longer limited to those of myocardial necrosis 
such as the troponins, which are the gold standard markers for cardiac injury, but have expanded 
to include markers of hemodynamic stress, inflammation and vascular damage [12].  However a 
search for markers of myocardial ischemia as well as other stages that precede myocardial 
necrosis including disruption of the plaque, oxidative stress, and tissue hypoxia is warranted 
[13].  Identification of early stage biomarkers may aid in the clinical outcome for patients.  
Currently, the ECG is a widely available strategy utilized to detect changes in ischemia due to its 
low cost, high feasibility, and widely available characteristics [14].  Rapid diagnostic testing as 
well as early detection and treatment are critical in identifying those patients who could benefit 
most from therapeutic interventions and to prevent irreversible damage [15].  Therefore, 
understanding the pathophysiological mechanisms which result in the progression of 




critical in understanding the underlying risks associated with ACS and in identifying potential 
biomarkers to identify patients most at risk for developing ACS.    
Pathophysiology of ACS: 
One of the most common causes of ACS is plaque formation as a result of atherosclerosis and 
subsequent rupture of the plaque [16].  Development of atherosclerosis or atherogenesis, occurs 
due to a number of factors which together are the root cause for plaque formation.  Increased 
lipids such as low density lipoprotein (LDL) cholesterol in the blood is transported and deposited 
in the lumen of blood vessels resulting in the thickening of artery walls and abnormal features of 
the blood vessel due to endothelial cell injury [17-18].  A pathological inflammatory response 
ensues due to the initial damage that occurs in the blood vessel wall with increased infiltration 
and adhesion of monocytes to the surface of the vessel.  Monocytes eventually differentiate into 
a macrophage cell in an attempt to ingest the oxidized LDL particles [19].  Ingestion of oxidized 
LDL particles by macrophages, now known as ‘foam cells,’ further escalates the inflammatory 
response which leads to vascular smooth muscle cell (VSMC) activation [20].  As the disease 
progresses, activated VSMCs begin to migrate to the neointima portion of the vessel where they 
begin to proliferate and activate the extracellular matrix generating a fibrous cap [21].  The 
inflammatory events that occur in the setting of atherosclerosis are correlated with increased 
episodes of ischemia in patients who present with ACS [20].  Atherosclerotic plaques are divided 
into two categories, unstable and stable and the likelihood of a plaque becoming unstable and 
rupturing depends on the type and composition of the plaque [22-23].   Typically, unstable 
atherosclerotic plaques include a thin fibrous cap and a lipid-rich core that usually occupies 




are characterized by having a supportive fibrous cap that is rich in extracellular matrix, and lipid 
content containing less than 40% of the plaque volume.  Unstable plaques which are more prone 
to rupture are an impending cause of ACS [25].  Although plaque rupture is the most common 
cause of ACS, other less common causes include drug use, spontaneous coronary artery 
dissection and coronary embolism [9].   
In the context of diabetes, several studies have demonstrated how the metabolic changes, 
triggered by high blood glucose, accompany the structural and functional modifications in the 
diabetic myocardium [26-27].  Elevated blood glucose levels are prevalent in patients admitted to 
hospitals with ACS and are often an indicator of poor prognosis in these patients [28-30].  
Because of several contributing factors occurring together including hyperglycemia, increased 
platelet aggregation and inflammation, diabetic patients with ACS are at greater risk for 
developing adverse cardiovascular complications [31].  Pathophysiological changes and adverse 
effects mediated by hyperglycemia including increased inflammation, apoptosis and cellular 
injury and oxidative stress alter the efficient functioning of the cardiomyocytes and contribute to 
the increased risk of the diabetic population developing cardiovascular complications. [29, 32].  
Build-up of atherosclerotic lesions leading to infarction as well as development of diabetic 
cardiomyopathy are processes that progress slowly over time and may be asymptomatic 
impacting the severity of the disease.  Patients often do not seek medical help until severe 
damage has already occurred. 
Genetics 
It has long been appreciated that coronary artery disease is linked to family history.  Gaining 




studies.  Understanding pathophysiological features of atherosclerosis and the critical steps 
which lead to progression of this disease has been a guide in determining possible genetic factors 
linked to ACS.   Therefore, genes which encode some of the main molecules that significantly 
impact atherosclerosis including platelet function and aggregation (thrombus development), lipid 
metabolism, characteristics of the blood vessel and vascular function are main targets for genetic 
characterization.  In the search for candidate genes, most studies have looked at polymorphisms 
or variants in a particular gene, in order to identify whether they occur more or less in patients 
affected with a myocardial infarction [33-34].  Increased risk of MI has been linked to several 
polymorphisms.  High blood levels of coagulation factor VII and variants in the cholesterol ester 
transfer protein are associated with several conditions including diabetes mellitus, glucose 
metabolism, platelet and leukocyte function, and hyperlipidemia and have been associated with 
increased risk of MI [35].  Despite the fact that several polymorphisms have been identified, 
several inconsistencies between studies exist and not all polymorphisms have been shown to be 
associated with the risk of MI.  Hence, clinical application of these polymorphism results has 
been limited.  Regardless, the identification of possible targets has provided a platform for 
understanding the genetic basis of disease onset and progression and with more work could be 
utilized to improve patient prognosis.      
Treatment: 
The availability of treatments for acute coronary syndromes has grown over the past few years 
due to increased awareness of their pathophysiology.  Currently available therapies aim to restore 
blood flow to infarcted tissue such as the use of thrombolytic therapy, percutaneous coronary 




toward restoring blood flow to infarcted areas (reperfusion) as soon as possible in order to 
salvage myocardial tissue and to reduce infarct size.  PCI has emerged as the gold standard 
option for reperfusion of infarcted tissue.  Several clinical trials have demonstrated the 
importance of early treatment since prompt treatment was associated with improved clinical 
outcomes in [15, 38]  While widely available, one of the main disadvantages of fibrinolytic 
therapy is that platelet aggregation is increased due to increased thrombin production [39].  
Therefore, combining pharmacological therapies which target both platelet aggregation (anti-
platelet) and the thrombus (thrombolytic agent) has been shown to be effective in improving 
clinical efficacy[40].  While PCI alone is effective in achieving complete perfusion, this option is 
hindered largely due to the lengthy amount of time taken to implement this treatment.  Since 
patient outcome is largely determined by time taken to treat patients, combining pharmacological 
mechanical therapy can reduce delays in treatment and can also aid in reperfusion before any 
PCI is performed [39, 41].   
Favorable outcomes are determined mainly by prompt reperfusion of infarcted tissue.  However, 
the injury which occurs during reperfusion is well established, and a limitation of the current 
therapy is impacted by the amount of irreversible damage that occurs during reperfusion [42-43].  
Calcium overload, accumulation of oxygen-derived free radicals, and apoptosis all accompany 
reperfusion and are associated with increased tissue damage and poor outcomes in patients[39, 
44].  To further add to the conundrum, it has been estimated that only one-third of those 
undergoing PCI actually receive adequate myocardial reperfusion and in some patients, adequate 
coronary artery recanalization is achieved but a condition known as no-reflow may occur where 
adequate myocardial reperfusion is not achieved [45].  The resulting infarct size and scar in 




development of left ventricular remodeling [14].  Understanding myocardial substrate 
metabolism both with and without pathology will be critical to improve treatment plans for 
individuals and to minimize damage after an ischemic insult or MI. 
Stem and progenitor cell therapy in patients with AMI have been proposed to be used in 
conjunction with, or after PCI [46].  After recanalization, heart failure development is a major 
problem due to the significant loss of cardiomyocytes and lack of cardiac tissue regeneration.   
Extensive basic and clinical research focuses on the regenerative properties of resident cardiac 
stem cells and bone marrow (BM) derived cells, with the aim to repair damaged cardiac tissue in 
hopes of ameliorating ventricular remodeling that leads to heart failure [47].   
Several cell types including fetal cells, human umbilical cord derived stem cells, embryonic stem 
cells and skeletal myoblasts have been studied as potential candidates for cardiac tissue 
regeneration [48].   While studies have demonstrated improved contractile function and effective 
tissue regeneration after myocardial infarction via embryonic and fetal stem cell transplantation, 
the availability and ethical issues which surround the use of these cell types has greatly hindered 
research efforts and therefore urged the need to utilize other cell types [49].  The decrease in cell 
death, increase in the regeneration of myocardial tissue, and enhanced neovascularization are 
some of the proposed mechanisms shown to contribute to the beneficial effects of cell therapy.   
Several methods are currently available for the delivery of cells to the heart.  These include, cell 
mobilization, peripheral and intracoronary infusions, and direct intramyocardial injections [48].  
The use of pharmacological agents, such as granulocyte colony stimulating factor (G-CSF), is an 
attractive target due to its non invasive nature and has also been studied extensively in clinical 




questioned this method.  Intracoronary infusions are the most popular method for cell delivery 
currently used and the safety of intracoronary infusions have been established by several clinical 
trials, although no significant differences in morbidity and mortality are observed  in patients 
who received BM derived stem cells [50].  While several methods are available, including cell 
mobilization and intramyocardial injections, not much is known about the safety and efficacy of 
these delivery methods [51].   Furthermore, identifying the patients who would benefit most from 
cell therapy, the dose of cells to be delivered, the optimal cell type to be delivered and the 
mechanisms by which cell therapy exhibit beneficial effects all need further evaluation.  More 
clinical trials are needed in order to establish safety and efficacy of stem cell therapy in 
improving cardiac outcomes in patients with AMI.   
Ischemic Preconditioning: 
The term ischemic preconditioning (IPC) is a procedure where brief episodes of ischemia and 
reperfusion in alternating cycles are performed on a heart and have been shown to reduce infarct 
size.  Originally described by Murry, Jennings and Reimer, IPC performed on dogs was found to 
reduce infarct size and preserve ATP protecting the heart against lethal ischemia [52].  Since this 
observation, several studies have focused on this phenomenon and have tried to elucidate the 
mechanisms by which IPC protects the myocardium against lethal ischemia.  There are two 
windows of protection with IPC termed ‘early’ and ‘late’ windows.  The early window occurs 
rapidly and protection may last approximately 1-2 hours after IPC whereas the late window 
occurs about 24 hours after IPC and the protection can last for up to 3 days [53].  IPC has been 
shown to improve cardiac function through reductions in infarct size, apoptosis, endothelial 




including reductions in the rate of ATP utilization, depleted glycogen stores, and decreased 
lactate and proton accumulation have been proposed and shown to protect against lethal 
ischemia, however, these mechanisms are unlikely to explain the intense protection conferred by 
IPC [55].  Neuroendocrine triggers including bradykinin and opiods have been identified and 
shown to be released during ischemia initiating IPC protection through adenosine receptor 
mediated pathways [55-57].   
Adenosine receptors signal via phospholipases and diacylglycerol (DAG) to activate PKC and 
IPC protection.    Studies utilizing Protein Kinase C (PKC) inhibitors such as chelerythrine and 
staurosporine completely abolished protection via preconditioning, demonstrating the essential 
role of PKC pathway in preconditioning [58-59].  It has been proposed that the KATP channel is 
one of the targets of PKC and a proposed hypothesis is that PKC mediates cardioprotection by 
activating the KATP channel and targeting the mitochondrial permeability transition pore (mPTP), 
both of which are important factors when considering cardiomyocyte viability after stress 
induction [60-61].  Several other kinases including mitogen-activated protein kinase (MAPK), 
PI3 kinase, AKT and ERK have been shown to be involved in preconditioning by inhibiting 
formation and opening of mPTP [55].  Various PKC inhibitors and activator peptides of PKC 
translocation have been developed and studied in mediating cardioprotective effects.  These 
peptides can be effectively delivered into cardiomyoctes via tat-protein derived peptides and the 
cardioprotective effects mediated by these tat protein-derived peptides including δ-PKC inhibitor 
peptide δV1-1 and ε-PKC activator peptide ψεRACK, have been shown to reduce damage after 
ischemia reperfusion (I/R) [62-63].  Notably, ε-PKC activator peptide was demonstrated to 
exhibit ischemic preconditioning like effects.  The effect of PKC regulating tat peptides have 




The application of preconditioning in a clinical setting has garnered a great deal of attention, 
however since most patients with ACS already present with acute MI, identifying patients who 
would benefit most from this therapy has been difficult.  The beneficial effects of 
preconditioning require application of the therapy before the onset of lethal ischemia.  Because 
mimicking the exact animal experimental methodology in clinical patients is problematic for 
ethical reasons, surrogate end points have to be utilized [64].  Clinical coronary angioplasty 
studies where balloons are inflated sequentially causing brief episodes of ischemia have 
demonstrated attenuations in creatine kinase (CK) release, lactate production and elevations in 
ST segment [65-67].   Reductions in myocardial infarct and improvement in left ventricular 
ejection fraction (LVEF) was also observed in a separate study where coronary angioplasty 
balloons were inflated and deflated for up to six cycles following stent placement (ischemic post 
conditioning) [68]. Because of the extensive research investigating the mechanisms of IPC, 
numerous agents which mimic IPC have emerged and are available for use in humans including 
adenosine agonist AMP579, sildenafil, erythropoietin, and atrial natriuretic peptide (ANP) [56, 
69-71].   
Metabolism of heart (Normoxia)   
The heart is a dynamic organ which can utilize several different substrates including fatty acids 
(FAs), glucose amino acids, lactate, and ketone bodies [72].  To meet the energy demands of 
contractile function, the heart utilizes enormous amounts of substrate.  The normal heart under 
aerobic conditions relies primarily on the oxidation of FAs rather than any of the other substrates 
for energy production due to the significant amounts of ATP produced per molecule of fatty acid 









Under normal fasting conditions, FAs are readily available in the blood and become rapidly 
oxidized by the heart for ATP generation [74].  After a meal, blood glucose is increased greatly 
resulting in a subsequent increase in insulin production.  The presence of insulin in the blood 
suppresses FA lipolysis which allows the heart to use glucose instead of FAs.  Oxidation of FA 
yields the majority of acetyl-CoA, approximately 60-90%, while pyruvate formed via glycolysis 
yields 10-40% [72, 75].  Acetyl-CoA formed after FAs and glucose oxidation is fed into the 
Kreb’s Cycle producing NADH and carbon dioxide.  ATP is ultimately generated through 
oxidative phosphorylation which occurs within the mitochondria.  As electrons pass through the 
respiratory chain in the mitochondria, a proton gradient created across the inner mitochondrial 
membrane serves as the driving force by which ATP is produced.  Protons are shuttled through 
the ATP Synthase allowing phosphorylation of ADP [76].  In a normal healthy heart, substrate 
metabolism remains robust to meet the energy demands for contractile function.   
 
Metabolism of heart (Ischemia) 
Appreciating substrate metabolism in the normal healthy heart is critical in order to comprehend 
substrate metabolism in stressed states (Figure 1 adapted from [73]).  In times of stress, such as 
during myocardial infarction, there is an imbalance between the rate of oxygen consumption and 
metabolite delivery necessary to meet the energy demands of the working heart [77].  During 
ischemia, the heart rapidly shifts from primarily oxidizing FAs for energy, to oxidizing pyruvate 
generated via glycolysis as an adaptive or maladaptive mechanism in efforts to protect the 
myocardium during ischemic stress.  Studies using magnetic spectroscopy have been 
instrumental in establishing this metabolic shift and also to illustrate the imbalances in substrate 




90% of acetyl-CoA is formed via FA oxidation generating 95% of ATP [75].  The production of 
ATP via FAs oxidation is however more energetically costly than glucose oxidation.  Beta 
oxidation of FA consumes about 12% more oxygen than glucose per ATP molecule generated.  
During the time of an ischemic insult, the heart switches to glucose utilization which 
dramatically reduces oxygen consumption and thus allows for continued ATP production, albeit 
at a much lower yield.   
 
GLUT 1 (insulin insensitive) and GLUT4 (insulin sensitive) are the two isoforms present in the 
myocardium and have been shown to be responsible for glucose uptake in the heart [79-80].  
After a meal when glucose and insulin are increased or in the event of an ischemic insult, 
GLUT4 translocates from intracellular compartments to the plasma membrane and facilitates 
glucose uptake by cardiomyocytes [81].  Once inside the cell, glucose becomes phosphorylated 
by the enzyme hexokinase forming glucose-6-phosphate (G-6-P).  Once formed, G-6-P can 
either enter the glycolytic pathway or be converted into glycogen for storage.  The fate of G-6-P 
to either enter glycolysis or to be converted into glycogen depends on several factors.  Firstly, the 
cytosolic ratio of NADH/NAD+  greatly influences glycolytic flux since the enzyme 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) utilizes NAD+ in order to convert 
glyceraldehyde-3-phosphate into 1,3 diphosphoglycerate.  The formation of 1,3 
diphosphoglycerate further proceeds along in the glycolytic pathway creating pyruvate.  
Secondly, the rate of glycolysis or glycogen synthesis depends on the activity of 
phosphofructokinase which converts fructose-6-phosphate into fructose 1,6 bisphosphate.  This 
is the key rate-limiting regulatory step in glycolysis and one which commits glucose to the 




uptake glucose and shunt towards the glycolytic pathway.   Earlier steps begin as previously 
described with GLUT4 transporters translocating to the plasma membrane to rapidly uptake 
glucose into the cardiomyocytes starved for energy.  The duration and severity of ischemia will 
determine the extent of abnormalities observed in metabolism and the contribution glucose 
provides to energy production.  During periods of severe ischemia where flow is eliminated, 
ATP becomes significantly depleted which leads to a rapid increase in glucose uptake and 
glycolytic flux.  If severe ischemia is prolonged over time, inhibition of glycolysis will 
eventually occur due to an accumulation of glycolytic metabolites/cofactors and tissue necrosis 
will develop.  A moderate ischemic insult, on the other hand, will result in a shift towards 
anaerobic metabolism with an increase in lactate production.   It was mentioned earlier that the 
yield of ATP via glucose oxidation is far lower than that of FA oxidation; however, maintenance 
of glycolytic flux during ischemia is key in preserving the myocardium and salvaging tissue.  
Even though lower than FA oxidation, the ATP generated during glycolysis is sufficient to 
preserve myocardial tissue after an ischemic insult since it supplies enough energy to support 
functioning of enzymes including the Na+/K+ ATPase as well as the Ca2+-ATPase.  Several 
studies in the literature have shown the benefits of sustaining glycolytic flux during ischemia and 
preservation of myocardial tissue [82-83].  Elucidating myocardial substrate metabolism can aid 
in the development of therapeutic agents which could target these substrates in order to increase 
glucose oxidation and improve myocardial function during and after I/R.   
 
Because increased fatty acid beta oxidation during I/R is associated with negative outcomes, a 
beneficial strategy would be to develop therapeutic agents which will increase glucose and 




accomplished and will now be discussed in more detail.  A measure that can be applied to 
increase myocardial glycolysis is by increasing glucose uptake.  Animal studies have illustrated 
the beneficial effects glucose-insulin-potassium (GIK) in improving cardiac function, while 
clinical studies have varied greatly [84-85].  Because insulin is known to suppress lipolysis in 
adipocytes, insulin emerges as a potential therapeutic agent serving to increase glucose 
oxidation.  This has been demonstrated clinically in patients with ischemic heart disease that 
were administered infusions of insulin which improved certain indices used to evaluate heart 
function including improved left ventricular ejection fraction [86].  GIK infusions administered 
to patients, improved patient outcome as a result of decreased FFA lipolysis and a reduced 
availability of FFA, therefore shifting β-oxidation to glycolysis and glucose oxidation [87-92].   
Furthermore, decreased infarct size, a reduction in ventricular dysrhythmias and an overall 
increase in survival were all associated with use of GIK [93-94].  However, numerous clinical 
studies utilizing GIK have varied greatly in its ability to attenuate injury after acute myocardial 
infarction.  In most of the clinical trials, GIK treatment was a fixed dose cocktail which failed to 
adjust to intravenous glucose administration [95].  Immediate increases in glucose 
concentrations, depending on the GIK cocktail used, immediate increases in glucose levels could 
result (when compared to pretreatment levels).  Hyperglycemia is known to be associated with a 
host of negative outcomes including thrombus formation and inflammation [96-97].  
Additionally, most of the clinical trials utilizing GIK did not take the metabolic status of patients 
into account, which could influence the effect of GIK [95].  Glucose levels in patients either 
before or after GIK administration varied between studies and the time and delivery of GIK 
administration greatly varied between clinical studies [95].  Because of these variations and 




reperfusion and thrombolytic therapies, studies demonstrated that infusion of GIK in diabetic 
patients decreased mortality [98].  In addition to increasing glucose uptake, therapies aimed at 
inhibiting fatty acid oxidation or directly activating PDH have also been studied as methods to 
increase glycolytic flux.  Clinical studies in patients with heart failure that have utilized 
dichloroacetate (DCA), a PDH kinase inhibitor, have demonstrated improved cardiac 
contractility and improved glucose oxidation [99-100].  Carbohydrate metabolism is increased 
via direct activation of PDH and provides sufficient ATP needed for sustaining heart function 
through pyruvate oxidation.  Acipimox, a niacin derivative and antilipolytic agent, is another 
therapy utilized, in the aim to inhibit FA oxidation [101-102].  Studies utilizing Acipimox have 
shown inhibition of FA oxidation and increases glucose oxidation [103].  
 
It is established that decreasing FA β-oxidation while increasing glucose uptake and oxidation is 
key in maintaining optimal contractile function after I/R in vitro, however, the role of FA β-
oxidation in protecting ischemic myocardium is evolving.  Studies utilizing heart specific 
lipoprotein lipase knockout (hLpL0) mice models demonstrated that hearts were able to increase 
glucose uptake and glucose oxidation via increased PDH activity, while FA oxidation rates were 
decreased [104].  In these studies, it was observed that following abdominal aortic constriction, 
hLpL0 mice died suggesting that increased glucose oxidation alone was insufficient to protect 
the myocardium after chronic injury [104].  The concept of fatty acid β- oxidation inhibition 
arose due to studies illustrating a correlation between increased serum fatty acids and increased 
mortality.   It was observed by Oliver et al, that the death rate was higher in patients with high 
levels of fatty acids in their serum compared to those with lower serum fatty acids [105].  The 




Increased serum fatty acids effectively inhibit glucose oxidation [106-107].  A major step in fatty 
acid oxidation is the delivery of FAs to the mitochondria and the key enzyme which mediates 
this process is Carnitine Palmitoyltransferase-I (CPT-1) [108].  Additionally, L-carnitine is 
important in the delivery of FA to the mitochondria via L-carnitine mediated transport and 
influences PDH activity and glucose oxidation [108-109].  Pharmacological agents aimed at 
inhibiting CPT-1 effectively reduce FA oxidation and also activate PDH.  The beneficial effects 
of L-Carnitine administration has been shown clinically to increase glucose oxidation, stimulate 
PDH and improve contractile function upon reperfusion [110].  Ranolazine is a novel agent 
tested extensively in various animal models and has demonstrated efficacy by increasing glucose 
oxidation and in some instances inhibiting FA oxidation.   In isolated mitochondria studies, 
trimetazidine, another anti-ischemic drug, has demonstrated a similar effect of increased glucose 
oxidation [111].  In hearts treated with trimetazidine, oxidative phosphorylation is inhibited 
when palmitoyl carnitine is the substrate suggesting that the drug inhibits FA oxidation [112].                      
 
Mitochondria pore and Ischemia-Reperfusion Injury: 
As is mentioned earlier, recanalization therapy is widely accepted as the gold standard of 
treatment of myocardial infarction, however it is also widely acknowledged that the dysfunction 
observed during reperfusion is in part due to irreversible damage that occurs during ischemia.  
Therefore several studies have focused on improving metabolism during ischemia in order to 
prevent ischemic injury and to promote improved functional recovery of the myocardium during 
reperfusion.  Despite these efforts, injury that occurs during reperfusion is exacerbated in part 
due to increased reactive oxygen species (ROS).  Current therapy aims to restore blood flow to 




of blood and oxygen.  White blood cells including neutrophils flood infarcted areas inducing 
inflammatory factors and free radicals in response to tissue damage.  Leukocyte accumulation 
due to increased adhesion to the endothelial surface contributes to further damage as blood flow 
in capillaries may become blocked or reduced.  Free radical species released by neutrophils 
cause damage to proteins, lipids as well as DNA resulting in further damage.   When considering 
substrate metabolism upon reperfusion, oxidative phosphorylation and oxygen consumption 
levels return to normal and a reduction in myocardial lactate levels are observed [74].  Several 
studies have shown that stimulation of glucose oxidation during reperfusion improves functional 
recovery due to a decrease in Ca
2+
 accumulation [113].   
 
The mitochondria are the main energy centers of the cardiomyocytes and generate the energy 
through oxidative phosphorylation that is necessary for efficient contractile functioning.  
Maintenance of mitochondria is vital for the survival of the myocardium after a stressful event 
[114-116].  Consisting of an outer and inner membrane, the mitochondria must maintain a pH 
gradient and a certain membrane potential to drive ATP production needed for maintenance of 
ion homeostasis.  During ischemia, oxidative phosphorylation reactions that occur in the 
mitochondria are disrupted, resulting in decreased ATP production, increase in phosphate, 
decrease in the intracellular pH, and an increase in intracellular Ca
2+
 concentrations.  The 




 which works to restore pH levels.  
Because ATP production during ischemia is severely compromised, the activity of this antiporter 
is disrupted causing Na
+
 overload.  As mentioned earlier, maintenance of glycolysis during I/R is 




 ion pumps to function efficiently.  










, and a decrease in intracellular pH [117].  Following imbalances of the 
Na+/H+ antiport is the Na+ dependent rise in intracellular Ca
2+




 exchanger.  
Studies have demonstrated decreases in Ca
2+




 exchanger is 









 overload proceeds are the conditions which greatly favor the opening of 
the mPTP [120-121].   
 
The extent of injury to the mitochondria is highly dependent on the duration and severity of 
injury during I/R that the mitochondria are exposed to, and ultimately decides the fate of the cell.  
The extent to which the pore remains open eventually will decide which mechanism of cell death 
(i.e. apoptosis or necrosis [121-123].  Under normal physiological processes, generation of ROS 
from the mitochondria does occur.  During reperfusion, the sudden influx of oxygen leads to a 
rapid induction of oxidative stress due to a much higher generation of ROS as well as a decrease 
in antioxidant defense systems such as superoxide dismutase and reduced glutathione [124].  The 
increased oxidative stress is accompanied by Ca
2+







 ATPase, ion pumps which work to increase calcium efflux and decrease 
calcium influx respectively.  Calcium overload which ensues effectively inhibits oxidative 
phosphorylation reactions and causes the opening of mPTP.  Once the mPTP opens, 
mitochondria lose the pH gradient and the membrane potential dissipates, both of which are 
required to generate ATP [125].  Eventually mitochondria become uncoupled with ATP 







While most studies have focused on improving tissue viability and regeneration, recent studies 
on autophagy have shown that processes which eliminate dead/damaged cells are also important 
in improving viability.  Autophagy (Auto=self) and (phagy=eat) describes a process triggered by 
a cell in order to rid itself of misfolded or damaged proteins, protein aggregates, and damaged 
organelles.  The process of autophagy occurs under normal physiological conditions and is 
necessary to maintain cellular homeostasis [126].  Upregulation of autophagy under pathological 
conditions such as myocardial ischemia has been the focus of recent studies to determine 
whether the process under pathophysiological conditions is adaptive or maladaptive [127].  
While some have shown conferred cardioprotection with autophagy upregulation, other studies 
have demonstrated the opposite[128] .  Understanding the induction of autophagy, as well as 
critical components of the autophagic process is warranted before discussion of autophagy 
mediated cardio protection or lack thereof can be addressed.   
 
The importance of constitutive activation of autophagy under basal conditions in the 
myocardium is noted in animal models, and in patients who present with Danon’s disease.  
Development of cardiomyopathy, as a result of left ventricular dilation and contractile 
dysfunction due to defects in lysosomal associated membrane protein 2 (LAMP2) is ultimately 
what patients with Danon’s disease face [129].  Deficiency in LAMP2 hinders the lysosome’s 
ability to digest and eliminate engulfed proteins resulting in the accumulation of damaged 
macromolecules including mitochondria [130].  Cardiac specific knockdown of Atg 5 gene in 
mouse models have further strengthened the significance of autophagy in maintaining cardiac 





Several proteins/kinases are involved in the initiation of autophagy induction and comprise 
complex signaling pathways involved in activating the process of autophagy.  Mammalian target 
of rapamycin (mTOR), phosphtidylinositol 3 kinase (PI3K), and AMP activated protein kinase 
(AMPK) are major players in the signaling cascade of autophagy induction and regulate its 
upregulation by sensing cellular status [132].  mTOR and AMPK are key sensors of nutrient 
status in a cell and are activated under periods of nutrient deprivation or starvation [132-133] .  
AMPK is located upstream of mTOR and when activated, AMPK phosphorylates and inhibits 
mTOR. 
 
The process of autophagy involves formation of an autophagosome which functions to engulf 
damaged proteins and organelles for elimination [134].  The discovery of Atg (autophagic) genes 
allowed for a greater understanding of the critical components involved in autophagosome 
formation.   More than 15 various Atg genes are required in the creation of the autophagosome 
[135].  Beclin-1 is the mammalian homolog of yeast Atg 6 and is a critical component in the 
early steps of the process [136].  Together with the class III PI3K, beclin-1 functions to recruit 
various proteins assist in the elongation phase of autophagosome development [137-139].  Once 
formed, fusion of the autophagosome containing damaged proteins or organelles with lysosomes, 
occurs.  The high pH level of lysosomes aids in the digestion and degradation of all materials 
inside the autophagosome.  For experimental investigation, several methods exist in order to 
observe or detect autophagy in tissue or cells.  Microtubule associated protein 1A/1B light chain 
3 (LC3) is used in several studies to identify autophagosome formation [140]).  Digestion of 




acids and amino acids to generate fuel in the form of ATP for the production of new cellular 
components [128].    
 
Aldose Reductase: 
So far, the glucose metabolism pathways during I/R that have been well established prior to 1997 
have been discussed here.  We were the first group to demonstrate impaired glycolysis after an 
increased flux via the aldose reductase (AR)/polyol pathway in the diabetic and non-diabetic 
hearts.  AR, a member of the aldo-keto reductase family is a monomeric NADPH dependent 
enzyme and the first, rate- limiting step in the polyol pathway [141-144].  It effectively utilizes 





Figure 2 as shown in [141]: Glucose flux via Aldose Reductase.  Glucose is metabolized by AR to Sorbitol.  




The second part of the pathway involves the enzyme sorbitol dehydrogenase (SDH) which 
utilizes NAD
+
 to convert sorbitol to fructose (Figure 2).  The polyol pathway was originally 
discovered in seminal vesicles where it was hypothesized that fructose was produced in order to 
sustain the developing spermatozoa [145].  Aldose reductase is widely expressed in several tissue 
types including lens, heart, and especially in the inner medulla of the kidney [146].  The 
production of sorbitol in the inner medulla of the kidney has been proposed to regulate and 




substrates efficiently including retinoids, 4-hydroxynonenal (4-HNE), 2-methylpentanal, 
methylglyoxal and glyceraldehydes [148-150].  The enzyme, however, has a greater preference 
for glucose than any of the other substrates and binds to glucose with a much higher affinity.   
Most of the substrates mentioned above bind to AR with Km values in the 8-50 micromolar range 
while AR has an anomer specific preference for D-glucose and binds to this specific glucose 
anomer with Km values in the micromolar range (0.66 μmol/L) [142, 151-152].   The activity of 
AR increases under elevated blood glucose levels as well as ischemic conditions [141, 153].  
Under ischemic conditions, an increase in nitric oxide (NO) has been shown to contribute to 
increased activation of AR.  Nitric oxide was further implicated in aldose reductase activation as 
use of NO inhibitors attenuated the increase in aldose reductase activity [154].  Furthermore, 
early studies confirmed, through the use of the aldose D-xylose as a substrate that myocardial 
NADPH reducing activity is due to increased activity of AR, as opposed to aldehyde reductase 
[154].  An increased glucose flux via AR inhibits glycolytic flux.  SDH utilizes NAD
+
 for 
sorbitol to fructose conversion resulting in an increased cytosolic ratio of NADH/NAD
+  
[141].  
In glycolysis, GAPDH also requires NAD
+
 for converting glyceraldehyde-3-phosphate to 1,3 
diphosphoglycerate conversion.  A competition between the two pathways develops due to 
limited NAD
+
 availability.  Glucose flux via AR during ischemia negatively impacts the 
myocardium by increasing oxidative stress, impairing ATP production as a result of altered 
glucose metabolism, and impairing calcium homeostasis [155].  All of the aforementioned are 
conditions which favor the opening of the mitochondrial permeability transition pore (mPTP) 
[156-160].  Preserving mitochondrial function is essential for normal recovery after I/R  [121, 
157, 159, 161].  Once opened, the mPTP has been implicated in upregulation of apoptotic and 




Animal models have become useful in demonstrating the negative effects of AR flux and 
expression in various pathologies.  Because the activity of AR in mice is much lower than that in 
humans or rats [146, 162], a transgenic mouse model was created in which human levels of AR 
(hAR) are expressed.  This transgenic mouse has AR expression and activity comparable to that 
found in humans.  Several studies have provided convincing evidence showing the negative 
association of increased flux via AR and certain pathologies.  Expression of human AR in 
macrophages of atherosclerotic plaques and has also been implicated in vascular injury due to 
increased growth of VSMCs and increased generation of ROS [163].   Transgenic hAR mice 
subjected to I/R displayed greater injury as demonstrated by several indices [141, 157, 164-165].  
These studies demonstrated using both the isolated Langendorff perfusion system ex vivo  and in 
vivo heart preparations, that hearts from hAR mice had decreased contractile function, increased 
generation of ROS, decreased production of ATP and increased damage to the mitochondria after 
I/R injury compare to wild-type counterparts [157, 162].  Studies utilizing rat models have 
shown increases in AR activity in hearts subjected to I/R.   
While extensive evidence demonstrating inhibition of AR to be protective, there are conflicting 
data sets which argue the opposite.  The role of AR as an essential mediator of the protective 
effects of late phase preconditioning (PC) has been addressed in earlier studies which show 
increased AR expression as a result of PC [166].  These studies allude to the antioxidant 
properties of AR which functions to neutralize against the accumulation of the toxic aldehyde 4-
HNE under I/R conditions, as well as protect against oxidative stress mediated arterial wall 
injury[167].  Despite these findings, several studies have established that inhibition of AR does 
not cause accumulation of toxic products such as malonyldialdehyde [168-172].   Further insight 




the role of AR in ischemic hearts as a protective enzyme.  It is clear from our studies and others 
that increased injury after I /R due to elevated levels of reactive oxygen species and poor 
functional recovery are associated with increased AR levels in mice overexpressing AR [162, 
173].  AR null mice, in contrast, were protected from injury associated with I/R [174].  Studies 
which demonstrate the ability of AR to attenuate accumulation of toxic lipid aldehydes utilized 
canine models of pacing induced heart failure, however AR expression in these models has been 
shown to be decreased [175].  In chronic diabetic rats, increases in both flux and expression of 
AR and SDH were increased, and in patients with ischemic and diabetic cardiomyopathies AR 
expression was also increased [3, 176].   These observances taken together, stress the importance 
of examining the role of AR in rodent models of heart failure.   
AR inhibition has been shown to reduce oxidative stress, and increase ATP levels promoting 
glucose oxidation and glycolysis [154, 162].  Additionally, reduction of cardiovascular 
complications including decreased restenosis and atherosclerosis has been shown in rodent 
models as a result of AR inhibition.  Aldose reductase knockout (ARKO) models, however, do 
not exhibit increased protection from atherosclerosis.  Compensation from other genes as a result 
from global AR elimination could have an effect on the phenotype and explain the lack of 
atheroprotection observed in ARKO mice [177].  Increases in cytosolic NAD
+
/NADH ratio due 
to inhibition of AR increases the availability of NAD
+
 and improves flux via glycolysis.  
Furthermore, experimental studies have shown decreased mPTP opening and a reduction in 
apoptotic cell death mechanisms which led to a reduction in injury after I/R after treatment with 
ARIs.  In the clinical setting, studies have shown that inhibition of AR improves cardiac function 
in patients with diabetes.  A study involving diabetic patients with neuropathy demonstrated that 




studies taken together highlight AR as an attractive therapeutic target in the quest to salvage 
ischemic myocardium.  The beneficial effects of AR inhibition are discussed in greater detail 
below.    
Aldose Reductase and Diabetes: 
Cardiovascular complications including hypertension, acute myocardial infarction and angina 
which ultimately result in congestive heart failure are the leading cause of death in diabetic 
populations [178-179].  Secondary microvascular complications including diabetic neuropathy, 
nephropathy, and retinopathy arise due to chronic hyperglycemia and its effects on endothelial 
dysfunction in the microvasculature.  Endothelial dysfunction as a result of high blood glucose is 
a characteristic early event of atherosclerosis which eventually leads to cardiomyopathy [180-
181].  The use of diabetic animal models has elucidated some of the pathophysiological 
mechanisms such as altered glucose metabolism and increased polyol flux that mediate 
development of complications through aberrant signaling.  Diabetic animal models have revealed 
abnormal substrate metabolism and molecular signaling which contributes to impaired 
myocardial function.  This is in particular due to decreased glucose uptake due to a decrease in 
the GLUT 1 and GLUT4 transporters which mediate glucose uptake.  Additionally, isolated 
diabetic rat heart models have shown that glycolysis is impaired, in part due to the increase in 
FFAs.  Under normal insulin conditions, lipolysis is inhibited thus increasing free circulating 
FFAs.  Under diabetic conditions and low insulin levels however, this inhibition is relieved.  The 
increases in FFAs are then able to further inhibit glucose uptake, further impairing glucose 
metabolism.  Consistent with the observation of decreased myocardial uptake in diabetic animal 




via FA oxidation triggers inhibition of PDH activity.  PDH kinase is largely responsible for the 
activity of PDH.  Dichloroacetate, a PDH kinase inhibitor has been utilized in diabetic rat models 
and has been shown to improve contractile function and increase glucose oxidation [108, 182].  
Production of advanced glycation end products (AGEs) as a result of increased polyol flux, and 
the phosphorylation of fructose further contribute to the conundrum of AR in mediating adverse 
effects especially in the diabetic setting.   The interaction of AGEs with the receptor for 
advanced glycation end products (RAGE) activates a mechanism implicated in increased injury 
after I/R [141, 183].  Figure 3 demonstrates a comprehensive visual of the interactions between 















Figure 3: Comprehensive overview of flux via Aldose Reductase, glycolysis and advanced glycation end product 
(AGEs) generation.  
In experimental studies, transgenic animals over-expressing hAR and made diabetic utilizing 
streptozotocin displayed greater losses in nerve conduction velocity and greater degeneration of 
nerve fibers when compared to wild-type diabetic mice [171].  To confirm the role of AR in 
contributing to this negative phenotype, transgenic, diabetic animals were treated with an ARI 
and significant improvement in nerve conduction velocity and reductions in nerve fiber 




was genetically ablated displayed significant reductions in nerve fiber atrophy and increased 
nerve conduction velocity.  For the most part, use of ARIs in diabetic animal models have either 
delayed onset of complications or prevented them altogether.  For clinical application and 
usefulness, reversing secondary complications which arise in diabetic populations is ideal.  This 
is because the secondary complications develop slowly over time and clinical symptoms from 
these complications which present in diabetic patients usually occurs after prolonged exposure to 
hyperglycemia and significant damage has already occurred.  Treatments which delay 
progression of disease would be beneficial to prevent severe damage but would greatly depend 
on early detection of complications.  Genetic variations in the human AR gene (ALD2 or 
AKR1B1) have been studied and linked to several diabetic complications including nephropathy, 
neuropathy and retinopathy [142, 184-186].  The onset of cardiorenal complications has been 
associated with genetic polymorphisms of AR in a type 2 diabetic Chinese population [187].  
Similarily, diabetic macroangiopathy was also associated with genetic AR polymorphisms in a 
Japanese type 2 diabetic population [188].   
Clinical studies of ARIs/complications: 
AR is an attractive target in diabetics due to its impact on glucose metabolism.  The presence of 
AR polymorphisms has been linked to several diabetic complications including cardiovascular 
disease and renal complications.  Human studies utilizing ARIs have demonstrated that in 
patients with neuropathy, administration of the ARI Zopolrestat for one year increased cardiac 
output and left ventricular ejection fraction (LVEF) when compared to patients treated with 
placebo [80].  In a different study, Tolrestat, another type of ARI, was found to hinder the 




administration in renal function have been established.  Both Tolrestat and Zopolrestat 
administration to type 1 diabetic patients was effective in reducing urinary albumin secretion 
[190-191].  Positive effects of AR inhibition are further supported in studies utilizing diabetic 
animal isolated heart models that have been perfused with ARIs and have been protected from 
adverse effects of high glucose [171].  Neuropathy consists of defects in nerve conduction 
velocity as a result of elevated blood glucose levels. Clinical utility of ARIs in treatment of 
diabetes has been complicated due in part to the distinctive nature of complications in each 
patient.  To date, the majority of clinical trials have tested effects of ARIs on neuropathy.  Data 
from these trials are largely inconclusive due to a number of inconsistencies that are likely a 
result of differences in experimental design and in methodology.  Use of Alrestatin, Tolrestat, 
Ponalrestat, Fiderestat and Sorbinil have all been extensively studied in clinical trials have 
produced a range of results from no effect to some improvement, especially in trials investigating 
effects on neuropathy [192].  Additionally, toxicity problems in patients associated with the use 
of ARIs, especially Sorbinil, have proven to remain a tremendous problem [193].  In the diabetic 
setting, the potential of inhibiting AR in the heart has been emphasized in these key studies of 
diabetic complications in human subjects.  However, recapitulating human AR biology in animal 




CHAPTER 2: STATEMENT OF THE PROBLEM 
It has been established that an increased flux via aldose reductase (AR)/polyol pathway leads to 
impairment in metabolic ion and energy homeostasis and increases reactive oxygen species 
production which in part, leads to the opening of the mitochondrial permeability transition pore.    
The involvement of AR in mediating cardiovascular disease complications including restenosis, 
atherosclerosis, myocardial ischemia as a result of oxidative stress, endothelial dysfunction, and 
mitochondrial damage has become increasingly apparent.  The mechanisms by which AR 
modulates cardiac injury is evolving.  In my thesis, I investigated two important aspects which 
are likely to regulate tissue viability.  Hence, my focus has been on elucidating mechanisms of 
I/R injury, and clearance of dead/damaged proteins and organelles by autophagy (Figure 1).   
The objective of this thesis is to determine the signal transduction mechanisms by which the AR 
pathway contributes to the vulnerability of the myocardium to ischemic challenge.  The aim in 
Chapter 3 is to elucidate whether AR pathway mediated I/R injury is linked to changes in 
GSK3β phosphorylation.  Phosphorylation GSK3β has been demonstrated to be cardioprotective 
by reducing apoptosis and oxidative stress, as well as inhibiting mitochondrial pore opening 
[194].  We utilized transgenic mice broadly overexpressing hAR, as well as AR knockout mice 
(ARKO) to analyze changes in GSKβ phosphorylation.  We demonstrate that an increased flux 
via aldose reductase decreased phosphorylation of GSK3β and is linked to decreased cardiac 
recovery upon reperfusion.  The focus in chapter 4 is to determine whether an increased flux via 
AR and resultant I/R injury is mediated by changes in autophagy.  Our findings indicate that 
increased flux through the polyol pathway decreases autophagy and is associated with the 
worsening of the myocardium during I/R injury.  Finally in chapter 5, we discuss possible 




directions/experiments that can be performed to gain a better understanding of how 
cardioprotection is conferred via inhibition of GSK3β.   
 
 
Figure 1: The purpose of this thesis is to determine the signaling mechanisms by which an increased flux via 
Aldose Reductase mediates ischemia-reperfusion injury.  This thesis will focus on two distinct endpoints: Cell 




Chapter 3: Aldose Reductase modulates cardiac glycogen synthase kinase 3 beta 
phosphorylation during ischemia-reperfusion. 
 The following work has been submitted as a manuscript.  The data has been adapted from the 





Our objective was to investigate if AR mediated ischemia reperfusion (I/R) injury is linked to 
changes in phosphorylation of glycogen synthase kinase 3β (p-GSK3β), a key signaling protein 
that mediates cardioprotection and regulates numerous substrates including transcription factors 
and metabolic proteins..  We hypothesized that AR mediates I/R injury and impairs myocardial 
recovery through decreased phosphorylation of GSK3β.  Hearts from wildtype (WT), AR 
transgenic (ARTg) and AR knockout (ARKO) mice were isolated and perfused with and without 
GSK3β inhibitors SB216763 and lithium chloride (LiCl) under normoxic (30 minutes), ischemic 
(30 minutes) and reperfusion (60 minutes) conditions.  Lactate dehydrogenase (LDH) release, a 
marker of injury, was measured in the perfusate after reperfusion in the presence and absence of 
GSK3β inhibitors.  Left ventricular developed pressure (LVDP) measured to determine 
myocardial function was decreased in hearts from ARTg mice compared to WT and ARKO after 
I/R, while LDH release was increased in ARTg mice (p<0.05).  GSK3β phosphorylation was 
decreased in ARTg hearts as compared to WT and ARKO (p<0.05).  Increased Cytochrome C 
and decreased Bcl-2 expression was observed in ARTg hearts after I/R injury (p<0.05).  GSK3β 
phosphorylation and Bcl-2 expression was increased and Cytochrome C expression was 
decreased in ARKO as compared to WT (p<0.05). ARTg hearts perfused with SB216763 and 
LiCl had significant improvement in LVDP and exhibited decreased LDH release and decreased 
mitochondrial pore opening (p<0.05).  Treatment with SB216763 and LiCl increased p-GSK3β 
and Bcl-2 expression and decreased Cytochrome C in ARTg hearts (p<0.05).  Ad-hAR 
overexpressing cells, exposed to hypoxia (0.5% O2) for 30 minutes and reoxygenation conditions 
(20.9% O2) for 60 minutes had greater LDH release compared to control HL-1 cardiomyocytes 




with increased Cytochrome C and decreased Bcl-2 expression in ad-hAR overexpressing cells 
(p<0.05).  Treatment with PI3K/AKT inhibitor LY294002 increased cardiac injury demonstrated 
by increased LDH release in ARTg, WT, and ARKO hearts and in ad-hAR overexpressing cells.  
In summary, our data demonstrate that AR mediates I/R injury, in part, via modulation of 





While recanalization therapy using thrombolytic or surgical approaches have helped salvage 
ischemic myocardium, damage observed during reperfusion phase attenuates the benefits of 
these interventions [195-196].  Therapeutic strategies that target both the ischemic and 
reperfusion components of myocardial injury are likely to afford protection against acute 
myocardial ischemia-reperfusion (I/R).  In the quest for novel therapeutic strategies for acute I/R 
injury, we have focused on interventions that protect against myocardial I/R injury by 
modulating substrate metabolism.  In this context, we and others have demonstrated that the 
aldose reductase (AR) pathway contributes to myocardial I/R injury and that the inhibition of AR 
protects hearts from I/R damage [141, 157, 162, 173, 195-199].   
 
AR, a member of the aldo-keto reductase family is a monomeric NADPH dependent enzyme and 
the first, rate- limiting step in the polyol pathway [141-144].   Glucose flux via AR increases 
under ischemic conditions, [141, 153] even in the absence of diabetes, and negatively impacts 
the myocardium by increasing oxidative stress, impairing ATP production as a result of altered 
glucose metabolism, and impairing calcium homeostasis, conditions which favor the opening of 
the mitochondrial permeability transition pore (mPTP) [156-160].  Preserving mitochondrial 
function is essential for normal recovery after I/R [121, 157, 159, 161].  Opening of the mPTP 
has been implicated in upregulation of apoptotic and necrotic cell death mechanisms due to loss 
of membrane potential and ATP depletion [156-158].   
 
Elucidation of the mechanisms that contribute to cell death, have allowed for new insights and 




recanalization therapies.  GSK3β beta has emerged as a potential therapeutic target in the quest 
to treat myocardial ischemia-reperfusion injury and ischemic disease.  Under normal conditions, 
GSK is constitutively active and phosphorylates downstream targets.  There are two isoforms of 
GSK 3 which exist, GSK3α and GSK3β.  GSK3α and GSK3β are both regulated by 
phosphorylation and desphosphorylation; GSK3α on the Serine 21 and GSK3β on Serine 9 sites 
and Tyrosine 216 sites.  Of the two isoforms the phosphorylation and inhibition of GSK3β has 
been shown to contribute to enhanced cardioprotection, and has been demonstrated to be critical 
for survival as ablation of this isoform is embryonically lethal.  The role of GSK3β in mediating 
cardioprotection has been demonstrated in studies that have utilized various cardioprotective 
agents which increased the phosphorylation and inhibition of GSK3β resulting in a delayed 
opening of the mPTP and decreased apoptosis [194].   Various models of GSK3β inhibition 
including siRNA protein knockdown and small molecule pharmacological inhibitors have 
demonstrated that the threshold for ROS and Ca2+ induced mPTP opening is increased resulting 
in cardioprotection [194].  Furthermore, in studies utilizing transgenic mice with constitutive 
activation of GSK3β where the Serine 9 site is converted to Alanine, abolished these protective 
effects.   In vivo studies of I/R where inhibitors of GSK3β were added either before ischemia or 
before reperfusion demonstrated protective effects through a reduction in necrosis [200].  GSK3β 
is most notably known for its role in metabolism and as was explained in the introductory portion 
of this thesis, dysregulation of metabolism is an important factor and crucial contributor to 
decreased cardioprotection.  In addition to mediating glycogen storage by activating glycogen 
synthase (GS), GSK3β when active is known to phosphorylate and inhibit an important enzyme 
that regulates glucose oxidation, pyruvate dehydrogenase (PDH).  Maintaining glycolysis and 




of PDH is linked to decreased glucose oxidation [201].   Protection and preservation of cardiac 
tissue after administration of dicholoracetate, an activator of PDH, further supports the 
importance of maintaining glucose oxidation after I/R [202].  Interestingly, inhibition of GSK3β 
has been shown confer protection by decreasing inhibition of PDH, therefore rendering the 
enzyme active and increasing glucose oxidation [203].  The involvement of GSKs in various 
pathologies of the heart including hypertrophy, metabolism, cardiac cell death, and ischemic 
disease has been established in numerous studies utilizing various model systems.  In addition to 
its role in cardiac pathology, GSK3β has been implicated in other diseases including cancer, 
Alzheimer’s disease and bipolar disorders[204].  GSK3β, a serine/threonine kinase, has been 
identified by several studies as a key signaling protein which mediates cardioprotection and 
reduces cell death [203, 205].  GSK3β phosphorylates numerous substrates including 
transcription factors and metabolic proteins, and is involved in several cellular processes such as 
gene transcription, apoptosis and cell division [194, 206].  A wide spectrum of signaling 
pathways have been associated with the phosphorylation and inhibition of GSK3β on the Serine 
9 site [207-208].  Upstream pathways known to phosphorylate and therefore inhibit GSK3β 
include the PI3K/AKT, P70S6K/mTOR, protein kinase A and C (PKA, PKC) pathways.  
Regulation of GSK3β also occurs as a result of autophosphorylation on the Tyrosine 216 site 
which instead of inhibiting GSK3β, constitutively activates the kinase [203].  The canonical Wnt 
pathway is also involved in the regulation of GSK3β through protein interactions.  In this 
process, a protein complex formation of β-catenin, Axin, GSK and adenomatous polyposis coli 
(APC) proteins inhibit phosphorylation of downstream targets by GSK3β.  Once this protein 





We have previously demonstrated that increased metabolic flux through AR mediates I/R injury, 
in part, via changes in PKCα/β dependent signaling [209] and mPTP opening [157].  A number 
of  studies through the use of various experimental animal models have suggested that activation 
of specific PKC isoforms are involved in mediating cardiovascular injury through increases in 
cell proliferation and apoptosis [210].  Various isoforms of PKC exist, however in cardiac tissue, 
activation of α and β isoforms specifically have been implicated in mediating cardiac 
pathologies.  The expression and activation of the β isoform has been shown to be increased 
under pathological conditions such as I/R and diabetes [211-212].  Similarly PKCα has been 
implicated as a negative regulator of cardiac hypertrophy.  The use of PKCα null mice showed 
decreased susceptibility to heart failure and improved contractile function [213-214].   
 
Since phosphorylation of GSK3β is a key determinant of mPTP opening, we investigated if AR 
mediates I/R injury, in part, by adversely influencing GSK3β phosphorylation in murine hearts.   
It is unclear if phopshorylation of GSK3β is impacted by AR during I/R.  We utilized adult HL-1 
cardiomyocytes in an in vitro I/R injury model as well as ex vivo intact hearts subjected to I/R.  
Since mice have an AR protein expression and activity that is several fold lower than that in rats 
and humans [142, 162], we employed transgenic mice overexpressing human aldose reductase 
(ARTg) as well as an aldose reductase knockout mouse model (ARKO) to determine whether 






All animal experiments were approved by the Institutional Animal Care and Use Committees of 
Columbia University, New York University School of Medicine, Baylor college of medicine and 
conformed to the guidelines outlined in the National Institutes of Health Guide for Care and Use 
of Laboratory Animals (NIH Pub. No. 85-23, 1996). Male C57BL/6J mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME) and were used as control wild-type (WT) mice.  Male 
mice weighing 25–30 g at age 12-14 weeks were used in all experiments and maintained in a 
temperature-controlled room with alternating 12:12-h light-dark cycles.  Mice transgenic for 
human aldose reductase (ARTg) were obtained
 
from Dr. Mitsuo Itakura (University of 
Tokushima, Japan) and
 
a colony was established at our facility at NYU Medical Center.  Briefly, 
these
 
transgenic mice were developed by injecting full-length hAR
 
cDNA with a mouse major 
histocompatibility antigen class
 
I promoter [215].  Aldose reductase knock-out (ARKO) mice 
was generated as described recently [216].  The hAR transgenic and ARKO mice have been 
backcrossed >10 generations to develop a C57BL/6J background. 
2.2 Reagents 
The primary antibodies used were anti-phospho-GSK3β/totalGSK3β, anti-phospho-Akt (Thr308 
and Ser473)/total-Akt IgG, (Cell Signaling, USA); anti-cytochrome C IgG (BD Pharmingen, 
USA); anti-beta-actin IgG (BD Biosciences Pharmingen, USA). The secondary antibodies used 
were goat-anti-rabbit IgG-peroxidase antibody and rabbit-anti-mouse IgG-peroxidase antibody 
(Sigma, USA). All primary antibodies were diluted 1 1000 prior to use in western blot studies. 




purchased from Sigma, USA.  PI3K/Akt inhibitor LY294002 was purchased from Calbiochem, 
USA.   
Isolated perfused heart preparation: 
Experiments were performed using an isovolumic isolated heart
 
preparation as published and 
modified for the use
 
in mice hearts [157, 162]. Mice were anesthetized using a mixture of 
ketamine
 
(80 mg/kg) and xylazine (10 mg/kg). After deep anesthesia was
 
achieved, hearts were 
rapidly excised, placed into iced saline,
 
and retrogradely perfused at 37ºC in a nonrecirculating
 
mode through the aorta at a rate of 2.5 mL/min. Hearts were
 
perfused with modified Krebs-
Henseleit buffer containing (in
 
mM) NaCl 118, KCl 4.7, CaCl2 2.5, MgCl2 1.2, NaHCO3 25, 
glucose
 
5, palmitate 0.4, BSA 0.4, and 70 mU/L insulin. The perfusate
 
was equilibrated with a 
mixture of 95% O2-5% CO2, which maintained
 
perfusate PO2 > 600 mmHg. Left ventricular 
developed pressure
 
(LVDP) was measured using a latex balloon in the left ventricle. LVDP
 
and 
coronary perfusion pressure were monitored continuously
 




Hearts from WT, ARTg and ARKO hearts were perfused with Krebs-Henseleit
 
buffer throughout 
the I/R protocol.  After an equilibration
 
period of 30 min, global ischemia was performed for 30 
min followed by 60 min of reperfusion.   Perfusate temperature was maintained at
 
37ºC at all 
times during the protocol (i.e., during baseline,
 
ischemia, and reperfusion).  
To determine the link between AR and GSK3β after I/R injury, experiments were performed in 
the presence
 
of GSK3β inhibitors; SB216763 (3μM) and lithium Chloride (LiCl; 3mM) as well 






modified Krebs-Henseleit buffer containing 3 µM SB216763 or 3mM LiCl.  The doses of the 
inhibitors used in this study were based on the literature [217-219]. Inhibitors were present at the 
start of the equilibration period and continued throughout
 
ischemia and reperfusion.   
2.5 Mitochondrial swelling as a measure of MPTP opening. 
We employed mitochondrial swelling as a measure of MPTP opening. For measurement of 
MPTP opening, mitochondria were suspended in freshly prepared swelling buffer (0.2 M 
sucrose, 10 mM Tris-MOPS, pH 7.4, 5 mM succinate, 1 mM phosphate, 2 μM rotenone, and 1.0 
μM EGTA-Tris, pH 7.4) at 0.5 mg/ml, and swelling of mitochondria was monitored by decrease 
in absorbance at 540 nm in the presence of CaCl2 (5–100 μM).  Extent of pore opening was 




2.6 Culture and Transfection of HL-1 Cardiomyocytes 
Immortalized HL-1 cardiomyocytes were a gift from Dr William Claycomb (Louisiana State 
University, New Orleans, LA, USA) [220].   HL-1 cell line was chosen because they were 
derived from cardiac muscle cells obtained from mice [220].  Cells were plated on 
gelatin/fibronectin-coated six-well plates at a density of 4 × 10
5
 cells/well.  Human AR was 
overexpressed in HL-1 cardiomyocytes through viral mediated transfection.  Appropriate empty 
vector was transfected as a control.  For siRNA transfection, HL-1 cells were cultured in six-well 
plates and transfected with control or 40nM GSK3β siRNA using Lipofectamine RNAiMax 
reagent (Invitrogen, USA) according to the manufacturer’s instructions.  HL-1 cardiomyocytes 




workstation maintained at 37°C, followed  by 60 minutes of reoxygenation (20.9%O2).   In 
specific experiments, cardiomyocytes were treated with either GSK3β siRNA or PI3K/Akt 
(10µM) and PKCα/β inhibitors (1µM).   
2.7 Western Blot Analysis 
The tissue and cell protein concentration was determined using a DC Protein Assay kit (Bio-
Rad).  Equal amounts of protein were separated by SDS-PAGE (4–12% gradient gels), and 
proteins were transferred to a nitrocellulose membrane (Invitrogen). After blocking in 5% dry 
milk in 20 mM Tris-HCI, pH 7.5, 250 mM NaCl, 0.1% Tween 20 (TBST), membranes were 
incubated overnight with target primary antibodies (1 1000 dilution) according to the 
manufacturer's instructions. Membranes were incubated sequentially with secondary antibody for 
1 hr.  Blots were visualized with an ECL Horseradish Peroxidase Western Blot Detection System 
(Cell Signaling, USA), and quantitative analysis was performed using Image Quant TL software 
(Amersham). 
2.8 LDH Measurements 
Cardic injury due to I/R stress was assessed by measuring LDH release in the perfusates that 
were collected at the end of reperfusion. In HL-1 cardiomyocytes, injury due to 
hypoxia/reoxygenation (H/R) stress was measured in supernantants that were collected after H/R.  







2.9 Statistical Analysis 
All data are presented as mean value ±standard error of the mean (SEM).  Statistical significance 
of differences between various groups of heart was determined by ANOVA.  Post hoc 
comparisons were performed with Tukey or Dunnett procedures using GraphPad software as 





GSK3β phosphorylation expression in WT, ARTg and ARKO mice 
We utilized the isolated Langerdorff perfusion system in order to establish the influence, if any, 
of AR mediated ischemic injury on the phosphorylation and inhibition of GSK3β.  Previous 
studies have shown that the phosphorylation and inhibition of GSK3β is cardioprotective [203, 
205].  We first examined GSK3β phosphorylation at both the Ser9 and Tyr216 sites on GSK-3β 
after a 30 minute baseline period only.  Results show that there are no differences in GSK3β 
phosphorylation in WT, ARTg and ARKO hearts after baseline (Figure 1A and 1B).   
 
We then determined whether GSK3β phosphorylation was influenced after I/R.  Induction of I/R 
resulted in decreased inhibition of GSK3β demonstrated by decreased levels of p-GSK3β 
phosphorylated at Ser9 and increased levels of p-GSK3β phosphorylated at Tyr216 in ARTg 
mice hearts as compared to WT mice (Figure 1C, 1D; p<0.05).  Phosphorylation of GSK3β on 
the Ser9 site was also significantly increased in ARKO hearts as compared to WT (Figure 1C).  
Furthermore, ARTg hearts displayed a more than threefold increase in apoptosis compared to 
WT and ARKO hearts as measured by cytosolic Cytochrome C expression (Figure 1E, p<0.05).  
Similarly, anti-apoptotic protein, Bcl-2 expression was lower in ARTg hearts compared to WT 





Figure1: GSK3β phosphorylation expression in WT, ARTg and ARKO mice. Western blot analysis for a.) p-GSK3β-Ser9 and  
b.) p-GSK3β-Tyr216 under baseline conditions. c.) p-GSK3β-Ser9 and d.) p-GSK3β-Tyr216 under I/R conditions. e.) cytochrome 
C and f.) Bcl-2 in untreated WT, ARTg and ARKO mice hearts subjected to I/R.  No differences were observed in p-GSK3β 
expression after baseline conditions.  ARTg hearts showed decreased p-GSK3β inhibition compared to WT hearts after I/R. 
ARKO hearts had significant increases in p-GSK3β (Ser9) (p<0.05).  ARTg hearts displayed a more than threefold increase in 
apoptosis compared to WT and ARKO hearts as was measured by Cytochrome C expression (p<0.05).  Bcl-2 expression was 
significantly downregulated compared to WT and ARKO hearts.  ARKO hearts displayed significant decreases in apoptotic levels 
compared to WT (p<0.05).  WT-denotes non transgenic mice, AR-denotes AR transgenic mice (ARTg), and ARKO-denotes AR 




Pharmacological inhibition of GSK3β protects mice hearts upon I/R 
Because ARTg hearts displayed decreased inhibition of GSK3β, we next sought to further test 
the role of GSK3β in mediating I/R injury.  WT and ARTg hearts were treated with GSK3β 
inhibitors SB216763 and lithium chloride (LiCl), and were perfused under normoxic conditions 
for 30 minutes, followed by 30 minutes of ischemic conditions and 60 minutes of reperfusion 
conditions.  LiCl targets the inhibitory phosphorylation site of GSK3β-Ser9 and works to 
increase phosphorylation, while SB216763 targets the stimulatory phosphorylation site GSK3β-
Tyr216 and works to decrease phosphorylation.  Treatment with SB216763 and LiCl protected 
WT and ARTg mice hearts significantly as shown in figures 2a and 2b.  Improvement of LVDP 
(Figure 2A, p<0.05) was observed in WT and ARTg hearts treated with both SB216763 and 
LiCl.  Similarly, figure 2B shows decreased release of LDH (Figure 2B, p<0.05) in WT and 
ARTg hearts upon treatment with both inhibitors.  Treatment with LiCl and SB216763 
significantly inhibited GSK3β in both WT and ARTg hearts (Figures 2C and 2D; p<0.05).  WT 
and ARTg hearts perfused with both GSK3β inhibitors displayed markedly reduced apoptotic 
levels as was demonstrated by reduced cytochrome C (Figure 2E; p<0.05) expression and 





Figure 2: Pharmacological inhibition of GSK3β protects mice hearts upon I/R.  Determination of myocardial ischemic injury 
and function with and without GSK3β inhibitor treatment as shown by a.) left ventricular developed pressure (LVDP) recovery 
and b.) lactate dehydrogenase (LDH) release.  Western blot analysis for c.) p-GSK3β-Ser9 and d.) p-GSK3β-Tyr216 e.) 
Cytochrome C, and  f.) Bcl-2 in WT and ARTg hearts perfused with and without GSK3β inhibitors SB216367 and LiCl.  
Treatment with SB216367 and LiCl protected WT and ARTg mice hearts, significantly increased p-GSK3β inhibition (p<0.05) 
and decreased apoptosis.  WT-denotes non transgenic mice, AR-denotes AR transgenic mice, and ARKO-denotes AR null mice.  




Pharmacological inhibition of GSK3β abolished mPTP pore opening in mitochondria from WT 
and ARTg hearts, as shown by the mitochondrial swelling changes in response to increasing 
amounts of added calcium (Figure 3).   
 
Figure 3: Mitochondrial permeability in WT and ARTg hearts treated with and without GSK3β inhibitors SB216763 and LiCl 
and subjected to I/R.  Mitochondrial permeability transition pore opening (mPTP) was determined by monitoring swelling of 
mitochondria by measuring light scattering at 540 nm in the presence and absence of varying amounts of added calcium.  Pore 
opening was reduced in WT and ARTg hearts treated with SB216367 and LiCl in response to increasing calcium concentrations 
(p<0.05) WT-denotes non transgenic mice, AR-denotes AR transgenic mice (ARTg). (N=4-16/group).  
 
 
PI3K/Akt is a well-established upstream kinase that has been shown to phosphorylate and inhibit 
GSK3β at the serine residue.  We investigated Akt phosphorylation expression patterns in WT, 
ARTg and ARKO hearts after I/R.  To determine whether Akt is a key player by which AR 
mediates I/R injury, we utilized the PI3K/Akt inhibitor LY294002 during I/R.  Functional 
recovery was impaired in WT, ARTg and ARKO hearts in the presence of LY294002 as was 
demonstrated by significant decreases in LVDP (figure 4A; p<0.05).  As shown in figure 4B, 
LDH release was significantly increased in WT, ARTg, and ARKO hearts subjected to I/R stress 
in the presence of LY294002.  Marked reductions in p-Akt levels were observed in WT, ARTg, 
and ARKO hearts treated with LY294002 (Figure 4C; p<0.05).  Consequentially, p-GSK3β 




(Figure 4D; p<0.05).  Inhibition of the PI3K/Akt pathway resulted in significant increases in 
apoptotic levels as was measured by Cytochrome C expression (Figure 4E; p<0.05).  These data 
indicate that reduction in GSK3β phosphorylation is in part due to reduced PI3K/Akt 





Figure 4: Inhibition of PI3K/Akt.  Determination of myocardial ischemic injury and function, as shown by a.) left ventricular 
developed pressure (LVDP)  and b.) Lactate Dehydrogenase (LDH) release in WT, ARTg and ARKO perfused with and without 
PI3K/AKT inhibitor LY294002.  Western blot analysis for c.) p-Akt, d.) P-GSK3β-Ser9 and e.) Cytochrome C in WT, ARTg and 
ARKO hearts perfused with and without PI3K/Akt inhibitor LY294002.  Treatment with LY294002 decreased p-Akt and p-GSK3β 
levels in all 3 groups (p<0.05).  Cytochrome C levels were increased in WT and ARKO hearts (p<0.05), but not ARTg upon 
perfusion with LY294002.  WT-denotes non transgenic mice, AR-denotes AR transgenic mice (ARTg), and ARKO-denotes AR null 





 Akt and GSK3β phosphorylation expression in hAR overexpressing HL-1 Cells 
We employed the murine cardiomyocyte HL-1 cell line to identify where the signaling 
mechanisms are occurring in the myocardium.  We utilized siRNA to inhibit GSK3β and to 
determine whether GSK3β knockdown would decrease cellular injury and apoptosis.  Dose 
dependent concentrations of siRNA were utilized in order to determine the least amount of 
siRNA required to efficiently knock down GSK3β.  Approximately 60% GSK3β knockdown 
was achieved in hAR overexpressing HL-1 cardiomyocytes with a 40nM siRNA concentration 
(Figure 5A). LDH measured in the supernatants after GSK3β siRNA transfection and H/R stress 
was markedly decreased in both control and hAR expressing cells (Figure 5B).  As was 
expected, GSK3β siRNA knockdown in control and hAR expressing cells significantly reduced 
p-GSK3β  levels (Figure 5C) and consequentially reduced cytochrome C levels (Figure 5D ; 





Figure 5: GSK3β siRNA knockdown in HL-1 cells.  Expression of GSK3β with concentration dependent siRNA knockdown.  
Determination of cardiac injury as determined by b.) LDH release in control and hAR siRNA knockdown of GSK3β *.  Western 
blot analysis of c.) p-GSK3β and d.) Cytochrome C expression in control and hAR overexpressing cells transfected with GSK3β 
siRNA .  No change in LDH release was observed in control and hAR overexpressing cells exposed to 30 minutes of Normoxia 
alone.  Thirty minutes of hypoxia followed by 60 minutes of reoxygenation increased LDH release (p<0.05) while inhibiting 
GSK3β with siRNA significantly reduced LDH release and injury (p<0.05).  GSK3β siRNA knockdown significantly reduced p-
GSK3β expression in both control and hAR  overexpressing cells.  Inhibition of GSK3β significantly reduced apoptotic levels in 
both control and hAR overexpressing cells.  *Error bars not visible.  Control Normoxia: SEM±0.003, Control hAR SEM±0.006, 
Control GSK3β siRNA: ± 0.005) 
 
HL-1 cells expressing hAR and empty control vectors were exposed to H/R stress to determine 




expression of p-Akt was significantly reduced in ad-hAR expressing cells during H/R stress 
(Figure 6A; p<0.05).  Decreased expression of p-Akt corresponded with decreased 
phosphorylation and inhibition of GSK3β.  We analyzed the expression of p-GSK3β at both the 
Ser9 and Tyr216 residues in hAR overexpressing cells and found that phosphorylation of GSK3β 
was significantly decreased on the Ser9 site and increased on the Tyr216 site (Figures 6B and 
6C; p<0.05), after H/R.  As was observed in ex vivo heart I/R injury, decreased phosphorylation 
and inhibition of GSK3β correlated with increased cell death after H/R as was measured by the 
increased expression of Cytochrome C and reduced Bcl-2 levels in hAR overexpressing cells 
(Figure 6D and 6E).  Additionally, cardiac injury as measured by LDH release in supernatants 
from hAR overexpressing cells after H/R was significantly increased (Figure 6F).  HL-1 cells 
overexpressing hAR as well as control cells were treated with the PI3K/Akt signaling inhibitor 
LY294002 during H/R to establish if Akt phosphorylation is a key event which mediates injury.  
As shown in figure 6G, both control and hAR overexpressing cells treated with the signaling 
inhibitor displayed marked increases in LDH release after H/R which was parallel to experiments 
in the ex vivo I/R heart preparations.  In addition to the increased LDH release, LY294002 
treatment significantly reduced p-GSK3β expression (Figure 6H; p<0.05) and resulted in 





Figure 6: HL-1 Cardiomyocyte studies.  Western blot analysis for a.) p-Akt, b.) p-GSK3β-Ser9 and c.) p-GSK3β-Tyr216) d.) 
cytochrome C and e) Bcl-2 in control and hAR overexpressing HL-1 cells subjected to H/R alone.  Determination of 
cardiomyocyte H/R injury as shown by f.) Lactate Dehydrogenase (LDH) release in control and hAR overexpressing HL-1 cell 
supernatants*  g.) LDH release in control and hAR overexpressing HL-1 cells treated with and without PI3K/Akt inhibitor 
LY294002.  Western blot analysis for h.) p-GSK3β-Ser9 and i.) Bcl-2 in control and hAR overexpressing HL-1 cells treated with 
and without PI3K/Akt inhibitor LY294002. Cells were incubated with LY294002 (10 µM) or its vehicle control DMSO for 1 hr, 
followed by 30 min of hypoxia and 1 hr reoxygenation (H/R).   Treatment with LY294002 decreased p- Akt levels, decreased 
inhibition of GSK3β and increased apoptosis in both control and hAR overexpressing cells.  LDH release in supernatants in both 
control and hAR overexpressing cells was increased with PI3K/Akt inhibitor LY294002 treatment.   *Error bars not visible.  
Control SEM±0.006 and hAR SEM±0.011. 
 
We have shown earlier that flux via AR leads to activation PKCα/β and that inhibition of 
PKCα/β with Gö6976 attenuates I/R injury [209]. In addition, PI3K/Akt pathway has been 




PKCα/β influence GSK3β phosphorylation, we treated HL-1 cells with PKC α/β inhibitor 
Gö6976 and subjected them to H/R stress.  PKC inhibition resulted in increased p- Akt (Figure 
7A; p<0.05) and p-GSK3β (Figure 7B; p<0.05) in ad-hAR expressing HL-1 cells.  Furthermore, 
treatment of HL-1 cells with Gö6976 resulted in a marked reduction of injury as shown by 
decreased LDH release (Figure 7C, p<0.05).  These data establish that AR modulates p-GSK3β, 
in part, via PKCα/β in cardiac cells. 
 
Figure 7: PKCα/β inhibition.  Western blot analysis for a.) p-Akt and b.)p-GSK3β.  Determination of cardiomyocyte injury as 
shown by c.) LDH release.  Treatment with Gö6976 resulted in decreased cellular injury and increase in p-GSK3β.  Cells were 







Previous studies demonstrated the important role of AR in mediating myocardial I/R injury [141-
142, 157, 162, 164, 173, 197-199, 209, 222].  Our goal in this study was to investigate if AR 
mediated I/R injury is linked to changes in phosphorylation of GSK3β and whether these 
changes would correlate with the impaired ability of the myocardium to recover after an 
ischemic insult.  Consistent with earlier results, we show that transgenic mice over-expressing 
human AR have increased I/R injury [157, 164, 209].  Hearts from ARKO mice demonstrated a 
significant increase in LVDP recovery as compared to WT mice.  Our earlier studies showed that 
inhibition of AR in WT mice reduced injury and also improved function.  We have previously 
shown that after treatment with Zopolrestat, an aldose reductase inhibitor (ARI), WT mice had 
significant decreases in the opening of the mPTP.  This can be explained in part because the 
expression of AR and flux via the enzyme increases after ischemia.   Here, we show that 
inhibition of AR (ARKO) significantly protects the myocardium as a result of increased 
phosphorylation of GSK3β and a reduction in apoptosis. We demonstrate that AR mediates I/R 
injury, in part, via decreased phosphorylation of GSK3β (Ser9) thereby impairing mitochondrial 
function, as well as functional recovery of the heart.    Phosphorylation of GSK3β was 
significantly decreased in ARTg mouse hearts as well as in hAR overexpressing HL-1 cells.  
Further experiments indicated that upon pharmacological inhibition of GSK3β, significantly 
higher levels of p-GSK3β was observed in ARTg hearts subjected to I/R and hAR 
overexpressing cells subjected to H/R.  The increases in levels of p-GSK3β correlated with 
decreased apoptosis in GSK3β inhibited ARTg hearts.  Our efforts to further elucidate the 
signaling mechanisms that contribute to the decreased phosphorylation of GSK3β highlight AKT 




PI3K/AKT pathway resulted in significant cardiac injury and impairment cardiac recovery 
function.  Treatment with PI3K/AKT inhibitor decreased p-AKT and p-GSK3β levels.  
 
Two mammalian isoforms of GSK3 have been identified; GSK3α and GSK3β [203].  During 
zebrafish cardiogenesis, GSK3α has been shown to be important for cardiomyocyte survival 
[223].  Further studies aided in clarifying the role of GSK3α by demonstrating improved glucose 
tolerance and insulin sensitivity as a result of global GSK3α loss in a murine model [224].  The 
GSK3β isoform regulates numerous cell processes including apoptosis and proliferation and has 
been shown to enhance cardioprotection in several studies [225-227].  The activity of GSK3β is 
regulated by phophorylation [194, 203, 206].  The phosphorylation and inhibition of GSK3β is a 
major component of its cardioprotective role.  Several studies have shown that the inhibition of 
GSK3β reduces apoptosis and confers cardioprotection depending on the degree and duration of 
inhibition [203, 208].  As is mentioned above, drastic inhibition through complete ablation of 
GSK3β is embryonically lethal due to TNF induced apoptosis.  Furthermore, short-term 
inhibition of GSK3β has been demonstrated to be protective, and as the duration of inhibition 
increases, the protective effects are lost due to heart failure as a result of NFκB inhibition, TNF-
induced apoptosis and myocyte loss  [203].  The contribution of sustained GSK3β inhibition to 
hypertrophy and growth of cardiac cells is evident since studies have demonstrated that 
constitutive activation of GSK3β alleviated these effects.  The question of whether GSK3β 
inhibition is protective after I/R has been disputed and the answer varies depending on several 
factors.  One important factor in considering the protective effects of GSK3β inhibition is the 
model used in the study.  Cardioprotection from preconditioning was inhibited in 




due to replacement of Serine 9 with Alanine.  This has been supported by several other studies 
which have demonstrated protection of the myocardium via GSK3β inhibition through other 
means including post conditioning, opiod-induced cardioprotection and via inhibition from the 
upstream PI3K/AKT pathway.  One study however, that utilized a GSK3α/β double knock-in 
model found that GSK3β inhibition is not necessary for protection in mice [205].  In this double 
knock-in model, both phosphorylation sites, Serine 21 on GSK3α and Serine 9 on GSKβ, were 
switched to alanine thereby preventing any phosphorylation on those sites.  Mice hearts from this 
model were isolated and subjected to I/R studies and it was found that infarct size after pre and 
post conditioning was greatly reduced compared to wild-type littermates suggesting that 
inhibition of GSK3β is not critical or necessary for protection.  It has been argued that cardiac 
specific overexpression of constitutively active GSK3β is linked to upregulations in atrial 
natriuretic peptide (ANP) which is known to alter cardioprotective signaling.  Similarly, the 
double knock-in model has been questioned since upregulation of other compensatory 
mechanisms could be contributing to the reduction of infarct size observed [205].   Furthermore, 
Nishino et al showed that pharmacological inhibition of GSK3β did not confer cardioprotection 
after preconditioning in mice, however when inhibitors were administered to rats, a reduction in 
infarct size was observed.  These differing results suggest a species specific response to 
pharmacological inhibition of GSK3β.  It is clear from these varying results that additional 
studies are needed to clarify the role of GSK3β in mediating caridoprotection are warranted.   
Therefore, when considering GSK3β as a therapeutic target, it is imperative to consider the end 
point in clinical outcomes since both the sustained activation and complete or sustained 
inhibition are both detrimental. The use of cardioprotective agents in a cardiomyocyte model has 




permeability transition pore (mPTP) opening [206].  Cardiomyocytes from mice with a 
constitutively active GSK3β were not protected upon treatment with cardioprotective agents.  
Other studies have shown a reduction in infarct size and an improvement in post ischemic 
cardiac function with the use of GSK3β inhibitors [203, 206] [228-229].  Consistent with these 
data of cardioprotection achieved by inhibiting the activity of GSK3β, our data show 
significantly enhanced phosphorylated GSK3β upon treatment with GSK3β inhibitors after I/R 
injury which correlated with  enhanced cardioprotection and a reduction in apoptosis in ARTg 
mice hearts. Analogous to heart ex vivo I/R experiments, siRNA knockdown of GSK3β in hAR 
overexpressing cells were protected against H/R stress.    
 
Several kinases upstream converge and inhibit GSK3β.  GSK3β has emerged as the integration 
point of many of
 
these pathways and plays a central role in transferring protective
 
signals 
downstream to target(s) [206, 230].  One of these upstream regulators includes AKT/PKB, a 
Ser/Thr kinase that has been shown to phosphorylate and inhibit GSK3β on the serine residue 
[207].  Fujio et al. have shown that AKT functions to promote cardiomyocyte survival and 
protects against I/R in the mouse hearts [231].  Our results show that the metabolic flux through 
AR mediates I/R injury, in part, via decreased AKT activation.  Furthermore, in hearts from WT 
and ARKO mice perfused with PI3K/AKT signaling inhibitors, we observed marked increases in 
LDH and impaired functional recovery during reperfusion.  The PI3K/AKT inhibitor resulted in 
marked decrease in the levels of phosphorylated GSK3β that consequentially led to increased 
cell death and apoptosis.  These data lead us to believe that AKT and GSK3β are key kinases 
which participate in the signaling mechanisms that mediate functional and cardiac recovery after 




resulted in the impairment of cardiac recovery which contributed to the vulnerability of the 
myocardium to recover after an ischemic insult.   
 
Studies by us [209] and others [232-233] have demonstrated that increased flux via AR leads to 
activation of PKC (α/β) in euglycemic and hyperglycemic conditions.  Furthermore, previous 
reports in the literature have alluded to the selective inhibition of PI3K/Akt as a result of PKC 
activation in endothelial cells [234].  The mechanism of PI3K/Akt inhibition has been attributed 
to activation of the PKCβ isoform in particular, due to hyperglycemia.  Hence, we investigated 
the role of PKC activation and GSK3β phosphorylation.  Naruse et. al., have demonstrated that 
inhibition of PKCβ resulted in improved glomerular endothelial cell function and improved 
insulin action [234].  Furthermore, translocation of PKCβII from the cytosol to membrane has 
been shown to contribute to I/R injury and either genetic or pharmacological inhibition of 
PKCβII protected ischemic cardiac tissue [212].  Additionally, activation of PKCα has been 
shown to contribute to cardiac hypertrophy and inhibition of this PKC isoform led to attenuation 
of inflammation, cardiomyocyte growth and cardiac hypertrophy [235].  Here, we demonstrate 
that inhibition of PKC, specifically α and β isoforms reduced cellular injury as demonstrated by 
reductions in LDH release upon treatment with PKC α/β inhibitor Gö6976.  Furthermore, we 
demonstrate that Akt and GSK3β phophorylation was increased in both control and ad-hAR HL-
1 cells treated with Gö6976.  Taken together, our 
data demonstrate that increases in AR flux leads 
to PKC activation followed by, decreases in Akt 
and GSK3β phosphorylation, and is linked to 




 Figure 8:  Schematic diagram.  Increased flux via AR after I/R resulted in generation of diacylglycerol (DAG) and activation of 
PKCα and β isoforms leading to decreased phosphorylation of Akt and GSK3β kinases.  Decreased GSK3β ultimately decreased 





While this study does not show the beneficial effects of AR inhibition with the use of an ARI, 
our group shows that p-GSK3β Serine 9 is significantly increased in the left anterior descending 
coronary artery (LAD) ligation in vivo model, after treatment with Zopolrestat, an ARI, 
compared to untreated groups (data not shown).   Secondly, the 30-minute ischemia and 60 
minute reperfusion end points have been argued to be the time at which most of the myocardium 
is in heart failure with near complete loss of ATP.  This may be correlated to the decreased p-
GSK3β observed in ARTg hearts compared to WT and ARKO.  Post translational modifications 
of proteins such as phosphorylation of GSK3β do not occur consistently, but rather have peak 
moments where phosphorylation is increased.  It may have been appropriate to conduct time 
course studies in order to evaluate p-GSK3β levels in response to I/R.   
  
In summary, our data demonstrates decreased levels of p-GSK3β in ARTg mice hearts as 
compared to WT hearts. Inhibition of GSK3β increased levels of p-GSK3β and was associated 
with decreased injury, improved functional recovery, and decreased apopotosis after I/R in 
ARTg hearts.  ARKO mice had increased levels of p-GSK3β, improved functional recovery, and 
decreased apopotosis after I/R as compared to WT and ARTg hearts.  Furthermore, we show that 
AR modulates changes in levels of p-GSK3β via AKT pathway.  Taken together, our data 




Our next phase of studies will determine mechanisms by which AR modulates GSK3β 






Chapter 4: The Role of Autophagy in Aldose Reductase Mediated Ischemia-Reperfusion 





Increased flux of glucose via the aldose reductase (AR) pathway is a key player in mediating 
ischemia/reperfusion (I/R) injury.  The role of autophagy in AR mediated I/R injury is unknown, 
therefore we sought to investigate whether an increased flux via AR impacts autophagy.     
cDNA plate array specific for autophagic genes demonstrated significant reductions in beclin-1 
transcript levels in ARTg hearts compared to WT.  Utilizing an isolated Langendorff perfusion 
system, hearts from adult wildtype (WT) mice, AR transgenic (ARTg) and AR knockout 
(ARKO) mice were isolated and and perfused under under normoxic conditions for 30 minutes, 
followed by 30 minutes of ischemia and 60 minutes of reperfusion.  Western blot analysis 
revealed significant reductions in beclin-1 protein expression in ARTg hearts and in hAR 
overexpression HL-1 cardiomyocytes.  Use of GSK3β inhibitors (SB216763 and LiCl) 
demonstrated no further reductions in beclin-1 protein levels in WT, ARTg and ARKO hearts.  
Autophagy inhibitor 3-methyladenine (3-MA) was utilized to determine whether autophagy is a 
key player in AR mediated I/R injury.  Lactate dehydrogenase (LDH), a marker of cardiac injury, 
and the functional recovery marker, LVDP, were measured in the perfusate after reperfusion in 
the presence and absence of autophagy inhibitor 3-MA.  Hearts from WT, ARTg and ARKO 
mice displayed significant increases LDH release.   LVDP was significantly impaired after 
reperfusion in WT, ARTg and ARKO hearts after perfusion with 3-MA and correlated with 
increased Bcl-2 expression.  Mammalian target of rapamycin (mTOR) is the key sensor of 
nutrient status in a cell.  Expression of mTOR was significantly increased in ARTg hearts 
compared to WT and ARKO.  Inhibition of mTOR with rapamycin significantly increased 
beclin-1 levels in WT, ARTg and ARKO hearts.  Inhibition of mTOR improved functional 




expression of p-Akt and p-GSK3β.   Taken together, our results indicate induction of autophagy 
in ARTg hearts is impaired and is correlated with the decreased ability of the myocardium to 





Conditions that trigger autophagy has been shown to occur under the I/R setting [236].  Several 
studies have demonstrated increased activation of autophagy under I/R conditions, however, the 
exact role of autophagy in the I/R setting has been under great debate; with existing evidence 
both for, and against the protective effects of autophagy induction [236].  It is clear that the role 
of autophagy under pathological conditions whether protective or maladaptive, warrants further 
investigation as there are inconclusive data on the subject.  Most of the studies on the topic have 
varied in the experimental models and designs, and so it is possible that the protective effects of 
autophagy are dependent on the duration, as well as the severity of ischemia and reperfusion.  
Additionally, the levels of autophagy, as well as upstream signaling pathways are critical in 
determining protective or detrimental effects of autophagy [237].       
 
Previous studies have shown that increased flux via AR is linked to increases in cardiac I/R 
injury [154-155].  Mechanisms by which AR mediates injury include decreased energy 
metabolism, increased reactive oxygen species (ROS), mPTP opening, impaired ion homeostasis, 
and involvement of the Jak/STAT pathway [157, 162, 209].  While several studies have provided 
insight into both the protective and detrimental effects associated with upregulation of autophagy 
during I/R, it is unknown whether an increased flux via aldose reductase (AR) influences any 
changes in autophagy.  Therefore, the first goal of chapter 4 is to determine whether AR 
influences autophagic induction, and second, to elucidate the role, if any, of autophagy in aldose 
reductase (AR) mediated I/R injury.  In order to determine whether there are any I/R related 
autophagy effects, we analyzed the expression of autophagy related gene, beclin-1, in WT, 





All animal experiments were approved by the Institutional Animal Care and Use Committees of 
Columbia University, New York University School of Medicine, Baylor college of medicine and 
conformed to the guidelines outlined in the National Institutes of Health Guide for Care and Use 
of Laboratory Animals (NIH Pub. No. 85-23, 1996). Male C57BL/6J mice were used as control 
wild-type (WT) mice.  Male mice weighing 25–30 g at age 12-14 weeks were used in all 
experiments.  Mice transgenic for human aldose reductase (ARTg) were obtained
 
from Dr. 
Mitsuo Itakura (University of Tokushima, Japan) and
 
a colony was established at our facility at 
NYU Medical Center.  Aldose reductase knock-out (ARKO) mice was generated as described 
recently [216].   
Reagents 
The primary antibodies used were anti-Beclin-1 IgG, anti-Bcl-2 IgG, anti mTOR IgG/anti-Total 
mTOR IgG (Cell Signaling, USA); anti-cytochrome C IgG and anti-beta-actin IgG (BD 
Biosciences Pharmingen, USA). The secondary antibodies used were goat-anti-rabbit IgG-
peroxidase antibody and rabbit-anti-mouse IgG-peroxidase antibody (Sigma, USA). Autophagy  
inhibitor 3-methyladenine (3-MA) was purchased from Sigma-Aldrich, USA.   
Isolated perfused heart preparation: 
Experiments were performed using an isovolumic isolated heart
 
preparation as published and 
modified for the use
 
in mice hearts [157, 162]. Mice were anesthetized using a mixture of 
ketamine
 
(80 mg/kg) and xylazine (10 mg/kg). After deep anesthesia was
 
achieved, hearts were 
rapidly excised, placed into iced saline,
 





mode through the aorta at a rate of 2.5 mL/min. Left ventricular developed pressure
 
(LVDP) was 
measured using a latex balloon in the left ventricle.  
Ischemia/reperfusion protocol: 
To determine the link between AR and autophagy after I/R injury, hearts from WT, ARTg and 
ARKO mice were perfused in the presence of autophagy inhibitor; 3-methyladenine (3-MA-
10mM).  Rapamycin (1 mg/kg, i.p.) was administered to WT, ARTg and ARKO mice 30 minutes 
prior to rapid excision of the heart..   The doses of the inhibitors used in this study were based on 
publications in the literature [238].  Inhibitors were present at the start of the equilibration period 
and continued throughout
 
ischemia and reperfusion.   
Western Blot Analysis 
The tissue and cell protein concentration was determined using a DC Protein Assay kit (Bio-
Rad).  Equal amounts of protein were separated by SDS-PAGE (4–12% gradient gels), and 
proteins were transferred to a nitrocellulose membrane (Invitrogen).   After blocking in 5% dry 
milk in TBST, membranes were incubated overnight with target primary antibodies (1 1000 
dilution) according to the manufacturer's instructions. Membranes were incubated sequentially 
with secondary antibody for 1 hr.  Phosphorylated and total mTOR expressions were transferred 
overnight in 4˚C and blocking was in 5% BSA in TBST.  Blots were visualized with an ECL 
Horseradish Peroxidase Western Blot Detection System (Cell Signaling, USA), and quantitative 






2.8 Lactate Dehydrogenase (LDH) Measurements 
Cardiac injury due to I/R stress was assessed by measuring LDH release in the perfusates that 
were collected at the end of reperfusion. In HL-1 cardiomyocytes, injury due to 
hypoxia/reoxygenation (H/R) stress was measured in supernantants that were collected after H/R.  
LDH was measured using the commercially available kits (Pointe scientific, Inc., USA) as 
published earlier. 
2.9 Statistical Analysis 
All data are presented as mean value ±standard error of the mean (SEM).  Statistical significance 
of differences between various groups of heart was determined by ANOVA.  Post hoc 
comparisons were performed with Tukey or Dunnett procedures using GraphPad software as 





Our aim was to determine whether autophagy was impacted by an increase in flux via AR.  To 
do this, we utilized the Langendorff perfusion system of isolated ex vivo heart preparations.  We 
examined beclin-1 levels as an indicator of autophagy upregulation.  We performed a cDNA 
plate array for specific autophagic genes including beclin-1, Atgs 3, 7 and 10, and BNIP3.  Our 
results demonstrate that in ARTg hearts, beclin-1 is significantly downregulated at the transcript 
level compared to WT hearts (Figure 1A).  Western blot analysis further confirmed this finding 
by illustrating a significant reduction in beclin-1 levels at the protein level in hearts from ARTg 
animals compared to WT and ARKO (Figure 1B).  HL-1 cardiomyocytes overexpressing human 
aldose reductase (hAR) and subjected to H/R also demonstrated a decrease in beclin-1 levels 
compared to controls (Figure 1C).  The reduced induction of autophagy in ARTg hearts 
correlated with a decrease in phosphorylation of Akt and GSK3β, as well as an increase in 
apoptosis as was demonstrated in the previous chapter by an increase in cytochrome C and 





Figure 1: Expression of Autophagy.  a.) cDNA plate array of specific autophagic genes.  b.) western blot protein expression of 
Beclin-1 in WT, ARTg and ARKO hearts and c.) protein expression of beclin-1 in control and hAR expressing HL-1 
cardiomyocytes.  Beclin-1 was significantly downregulated at both the transcript and protein expression in ARTg hearts 
compared to WT and ARKO in cardiac tissue (p<0.05).  Similarly, hAR overexpressing cardiomyocytes displayed significant 
decreases in beclin-1 expression.  
 
Because ARTg hearts displayed decreased upregulation of autophagy which was associated with 
a decrease in phosphorylation of GSK3β, we next sought to determine whether autophagy was 
GSK3β dependent or independent.  We determined whether inhibition of GSK3β influenced 
changes in beclin-1 levels.   WT and ARTg hearts were treated with GSK3β inhibitors 
SB216763 and lithium chloride (LiCl), and were perfused under normoxic conditions for 30 




conditions.  Western blot analysis indicated no further changes in beclin-1 levels (Figure 2) in 
hearts of GSK3β inhibition, suggesting that autophagy is unlikely to be downstream of GSK3β in 
our model. 
Figure 2: Expression of beclin-1 with GSK3β 
inhibition.  Protein expression of a.) beclin-1 with and 
without GSK3β inhibitors SB216763 and LiCl.  No 











To determine whether autophagy is a key player in AR mediated I/R injury, WT, ARTg and 
ARKO hearts were perfused with autophagy inhibitor 3-MA under normoxic (30 min), ischemic 
(30 min) and reperfusion conditions (60 min). Our data demonstrate that inhibition of autophagy 
significantly decreased autophagy as demonstrated by decreased beclin-1 levels (Figure 3A).  
Perfusion with 3-MA decreased cardiac function and increased injury after I/R.  Left ventricular 
developed pressure (LVDP) was found to be significantly decreased in hearts from WT, ARTg 
and ARKO hearts upon perfusion with autophagy inhibitor 3-MA (Figure 3B).  Furthermore, 
LDH measured after I/R as a marker for cardiac injury was found to be significantly increased in 




all three groups as indicated by a decrease in Bcl-2 protein levels in WT, ARTg and ARKO 
hearts (Figure 3D). 
 
Figure 3:Inhibition of Autophagy.  Western blot analysis of a.)beclin-1 in WT, ARTg and ARKO hearts treated with and 
without  3-methyladenine.  Determination of myocardial ischemic function and injury with and without autophagy inhibitor 3-
methyladenine treatment as shown by b.)LVDP and c.)LDH release.  Western blot protein analysis of d.) Bcl-2 in WT, ARTg and 
ARKO hearts treated with and without 3-methyladenine.  Use of 3-methyladenine resulted in significant decreases in beclin-1 
expression in WT, ARTg and ARKO hearts.  furthermore, inhibition of autophagy decreased functional recovery and increased 
cardiac injury and apoptosis.    
 
Mammalian target of rapamycin (mTOR) is the key sensor of nutrient status in a cell.  Upon 




phosphorylated mTOR (p-mTOR) in WT, ARTg and ARKO mouse hearts after I/R injury.  
Western blot analysis revealed that protein expression of p-mTOR was significantly increased in 
ARTg hearts compared to WT and ARKO hearts (Figure 4A).  The observed increase in p-
mTOR expression in ARTg hearts correlated with a decrease in beclin-1 levels, a finding 
consistent with data in the literature showing inhibition of autophagy when mTOR is 
phosphorylated [239].  Therefore, to determine whether mTOR is a key regulator of autophagy 
after I/R, hearts from WT, ARTg and ARKO were perfused with inhibitor of mTOR, rapamycin.  
Treatment of mice with rapamycin significantly improved LVDP and decreased LDH release in 
WT, ARTg and ARKO hearts (Figure 4B and 4C).  As expected rapamycin significantly 
decreased phosphorylation of mTOR in WT, ARTg and ARKO hearts (Figure 4D).  Use of 
rapamycin increased beclin-1 expression as demonstrated by western blot analysis in ARTg 
hearts when compared to WT and ARKO (Figure 4E).  Furthermore, treatment with rapamycin 
increased p-Akt and p-GSK3β expression (Figure 4F and 4G) and reduced apoptosis levels as 
demonstrated by decrease in cytosolic Cytochrome C levels in ARTg hearts (Figure 4H).  These 
data indicate that mTOR is a key factor in regulating the induction of autophagy after I/R.  In 
these studies, reduced induction of autophagy is associated with the impairment of the 
myocardium to recover after an ischemic insult.  Increased phosphorylation of mTOR correlated 





Figure 4:Role of mTOR in autophagy induction.  Western blot analysis of a.)p-mTOR in WT, ARTg and ARKO hearts.  
Determination of myocardial ischemic function and injury with and without mTOR inhibitor rapamycin treatment as shown by 
b.)LVDP and c.)LDH release.  Western blot protein analysis of d.) p-mTOR; e.) beclin-1; f.)p-Akt and g.)p-GSK3β; and 
h.)cytochrome C in WT, ARTg and ARKO hearts treated with and without rapamycin.  Use of rapamycin resulted in significant 
increases in beclin-1 expression in WT, ARTg and ARKO hearts.  Furthermore, rapamycin increased functional recovery and 





 In this study we investigated the role of autophagy induction in AR mediated I/R injury.  As we 
have shown before, increased flux via the AR pathway negatively impacts the myocardium by 
increasing oxidative stress, impairing ATP production as a result of altered glucose metabolism, 
and impairing calcium homeostasis, conditions which favor the opening of the mitochondrial 
permeability transition pore [240-243].    Studies that have utilized the isolated Langendorff 
perfused heart model have shown increased beclin-1 expression with preconditioning or 
resveratrol treatment, strategies that have been established to achieve cardioprotection [244-246].  
We show that autophagy related gene, beclin-1 is downregulated in ARTg hearts compared to 
WT and ARKO indicating decreased autophagosome formation and decreased induction of 
autophagy.  A decreased beclin-1 expression in ARTg hearts correlated with a decrease in p-
GSK3β expression, an increased cytosolic Cytochrome C, and decreased Bcl-2 protein 
expression.  Furthermore, when WT, ARTg and ARKO hearts were treated with autophagy 
inhibitor 3-MA, our study revealed that functional recovery in was markedly impaired.  
Consistent with this observation is the increased LDH released in all three groups after perfusion 
with 3-MA.   These results indicate that induction of autophagy in ARTg hearts is impaired and 
is correlated with the decreased ability of the myocardium to recover after an ischemic insult.  
Additionally, inhibition of autophagy impaired functional recovery and increased cardiac injury 
in WT and ARKO hearts. 
Induction of autophagy usually occurs under periods of stress such as nutrient deprivation or 
starvation.  In these times, induction of autophagy will generate the necessary substrates needed 
for generation of nutrients to support the cell and prevent further damage. There are several 




reason why autophagy is an evolutionary conserved process that occurs amongst eukaryotes.  It 
is required to maintain cellular and tissue homeostasis especially in certain periods including 
embryonic development.  Disregulation of autophagy has been shown to contribute to a myriad 
of diseases including cancer, diabetes, neurodegenerative diseases such as Alzheimer’s and 
cardiac diseases [247].  
 
There are several studies which have shown that autophagy is upregulated during the I/R setting 
[248-249].  Key events that occur during I/R which contribute to the impairment of the 
myocardium such as nutrient and ATP depletion, calcium accumulation, ROS accumulation and 
mPTP opening are all events which trigger the induction of autophagy.  Whether upregulation of 
autophagy is protective or not is a question that remains to be answered.  The use of the isolated 
heart models as well as in vivo heart models of ischemia reperfusion has further added to the 
controversy of the protective mechanisms offered by autophagy, or lack thereof.  
Cardioprotective agents such as sulfaphenazole as well as ischemic preconditioning, a method 
known to confer cardioprotection, have both been demonstrated to stimulate autophagy by 
increasing beclin-1 levels as well as the LC3II/LC3I ratio and consequentially reduce cell death.  
Adding to the confusion however, are studies where heterozygous knockdown of beclin-1 
(beclin-1 +/-) in mice resulted in a reduction of infarct size.  In cellular studies under hypoxia 
reoxygenation conditions, treatment with autophagy inhibitor 3-MA reduced cellular injury and 
decreased apoptosis [248, 250].  In contrast to this, other studies have shown that inhibition of 
autophagy with use of 3-MA or knockdown of beclin-1 was protective in cardiomyocytes after 
simulated ischemia reperfusion [251].  Cellular studies utilizing HL-1 cardiomyocytes have 





Mammalian target of rapamycin known for its role in mitochondrial metabolism, growth and 
proliferation, also plays a key role in nutrient regulation [252].  In the present study, we 
examined the role of mTOR in regulating autophagy in WT, ARTg and ARKO hearts.  This 
study demonstrates that intraperitoneal administration of rapamycin, inhibitor of mTOR, induced 
cardioprotection as is demonstrated by a reduction in functional recovery, upregulation in beclin-
1 protein expression and a reduction in apoptotic markers.    
 
This study establishes that an increased flux via AR reduced induction of autophagy and is 
associated with the vulnerability of the myocardium to recover after an ischemic insult.  Earlier 
chapters discussed the importance of maintaining mitochondrial integrity after I/R in order to 
preserve functional recovery.  One of the mechanisms by which autophagy in this setting may be 
protective is via mitophagy. Mitochondria that have been damaged during I/R conditions can 
potentially cause nearby mitochondria to become damaged.  During I/R, increased calcium 
accumulation in the mitochondrial matrix causes swelling and ultimately forces the mPTP to 
open dissipating membrane potential and depleting ATP.  Opening of the mitochondria is 
accompanied by cytochrome C release into the cytosol which activates apoptotic pathways.  
Similarly, increased mPTP opening causes a rapid rise in ROS and calcium release which 
ultimately will cause further damage to neighboring mitochondria.  Elimination of damaged 
mitochondria through autophagy, termed mitophagy, has been shown to be critical in 







3-methyladenine is a widely used inhibitor of autophagy [257-258].   In these studies we utilized 
3-MA to investigate the effects of autophagy inhibition in AR mediated I/R injury.  Some studies 
have shown that use of 3-MA may potentially confound results because it is a non specific 
inhibitor and targets other proteins which may implicate the finding in results.  Specifically, 3-
MA has been shown to promote glycogen breakdown and inhibit flux through 









My research has provided new insights into the signaling mechanisms mediating cardiac 
ischemic injury and autophagy.  Importantly, findings from my thesis research have established 
the hierarchy of AR driven signaling events which mediate cardiac I/R injury.  I have opted to 
present a brief review of my findings as bullets below.   
Research findings in chapter 3 demonstrate: 
1. Increased flux via AR decreased phosphorylation of GSK3β 
2. The decrease in GSK3β phosphorylation is mediated in part via increased PKCα/β 
activation and decreased Akt phosphorylation. 
3. Decreased phosphorylation of GSK3β was linked to increased mPTP opening and 
reduced cardioprotection 
The focus of chapter 4 is to investigate whether an increased flux via AR influences any change 
in autophagy induction and whether autophagy is linked to AR mediated I/R injury. 
Research findings in Chapter 4 demonstrate: 
1. Increased flux via AR decreased autophagy related gene Beclin-1 
2. Decreased Beclin-1 expression correlated with increased phosphorylation of mTOR and 
decreased phosphorylation of Akt and GSK3β (shown in chapter 3) 
3. Inhibition of autophagy with 3-Methyladenine correlated with decreased functional 
recovery, increased injury and increased apoptosis 
4. Inhibition of mTOR with rapamycin increased Beclin-1 expression, improved cardiac 
function, reduced injury, and decreased apoptosis. 
In the next part of this chapter, I provide insights into the important questions raised by my 




Concluding Remarks and Future Directions: 
We have demonstrated that an increased flux via AR decreased the phosphorylation of GSK3β 
leading to increased injury, and decreased cardiac function.  We further showed that inhibition of 
GSK3β utilizing specific and nonspecific inhibitors (SB216763 and LiCl respectively) conferred 
cardioprotection in AR transgenic mouse heart that has undergone ischemia-reperfusion (I/R).  
Currently, small molecule inhibitors of GSK3 that exist are not isoform specific but target both α 
and β isoforms.  Therefore, utilizing GSK3 β transgenic mice will be key in further confirming 
the cardioprotective role of GSK3β inhibition.  Two models that have been used to study the role 
of GSK 3 in cardiac tissue are the overexpression of cardiac specific constitutively active 
GSK3β, and the GSK3β knock-in model where the Serine 9 phosphorylation site is converted 
into Alanine therefore inhibiting phosphorylation.    
We and other have previously demonstrated that increased flux via AR leads to activation of 
PKC (α/β) in euglycemic and hyperglycemic conditions.  After glucose flux via the polyol 
pathway increases after I/R, PKC becomes activated through increased diacylglycerol (DAG) 
levels influenced by increases in the NADH/NAD
+
 ratio.  PKC activation, specifically the β 
isoform has been implicated in impairment of the myocardium to recover after an ischemic insult 
[212].  In our studies, we hypothesized that the increased PKC activation observed after I/R 
contributes to impairment of the myocardium through a decreased inhibition of AKT and 
GSK3β.  Furthermore, we expected that the inhibition of PKC (α and β isoforms) would result in 
an increase in AKT and GSK3β phosphorylation.  We utilized the PKC α and β inhibitor, 
Gö6976, in HL-1 cardiomyocytes and assessed phosophorylation patterns of AKT and GSK3β 
kinases.  Results revealed that inhibition of α and β isoforms of PKC increased phosphorylation 




strengthen our studies and to further illustrate the role of PKC α/β in AR mediated I/R injury, 
future studies should be conducted utilizing either PKCα -/- and PKCβ-/- mice bred on an ARTg 
background.  These efforts will help establish if ablation of these PKC isoforms will alleviate 
some of the detrimental effects of AR mediated I/R injury.  It might be argued that whole body 
knockout of PKC would activate other compensatory mechanisms which could confound 
interpretation of results.  Therefore, utilizing cardiomyocyte specific PKC α/β knockout animals 
might be more informative in efforts to elucidate and further characterize the role of PKC in the 
heart. 
 
Silent information regulators (sir2) are class III NAD+ dependent histone deacetylases and have 
been shown to increase lifespan in addition to protecting cells from apoptosis.  The mammalian 
ortholog of sir2 is Sirt1.   Studies utilizing cardiac specific overexpression of Sirt 1 demonstrate 
that a 2.5-7.5 fold increase in cardiac Sirt1 expression conferred cardioprotection and displayed 
resistance when exposed to oxidative stress [260].   As is explained in the introductory portion of 
this thesis, an increased flux via the polyol pathway decreases the availability of cytosolic 
NAD+.   Studies from our lab have shown that Sirt1 activity is reduced in ARTg hearts due to a 
reduced availability of NAD+ necessary for Sirt1’s deacetylase activity.  Furthermore, it has 
been shown that autophagy induction is upregulated through NAD+ dependent deacetylation of 
FOXO1 by Sirt1 [261].  In these studies, it would be interesting to investigate if the decrease in 
autophagy upregulation which contributes to I/R injury is mediated, in part, via decreased 
deacetylation of FOXO1.  Specific questions include: will increased flux via AR result in 
increased acetylation of FOXO1 in ARTg relative to WT and ARKO?  How does the acetylation 




FOXO1 can be assessed in WT, ARTg and ARKO hearts to determine if influenced by the 
decreased Sirt1 activity.  It is hypothesized that increased acetylation of FOXO1 will be 
observed in ARTg hearts relative to WT and ARKO hearts and will be associated with 
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